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Abstract

INHIBITION OF THE CALCIUM PLATEAU FOLLOWING IN VITRO STATUS
EPILEPTICUS PREVENTS THE DEVELOPMENT OF SPONTANEOUS RECURRENT
EPILEPTIFORM DISCHARGES
By Nisha Nagarkatti, A.B.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Robert J. DeLorenzo, M.D., Ph.D., M.P.H.
Professor, Departments of Neurology, Pharmacology & Toxicology, and Biochemistry &
Molecular Biophysics

Status epilepticus (SE) is a major clinical emergency resulting in continuous
seizure activity that can cause brain injury and many molecular and pathophysiologic
changes leading to neuronal plasticity. The neuronal plasticity following SE-induced brain
injury can initiate epileptogenesis and lead to the ultimate expression of acquired epilepsy
(AE), characterized clinically by spontaneous, recurrent seizures. Epileptogenesis is the
process wherein healthy brain tissue is transformed into hyperexcitable neuronal networks

xviii

that produce AE. Understanding these alterations induced by brain injury is an important
clinical challenge and can lend insight into possible new therapeutic targets to halt the
development of AE. Currently there are no means to prevent epileptogenesis following
brain injury; thus, the elucidation of mechanisms of epileptogenesis will be useful in
preventing the long-term clinical sequela. It has been demonstrated in vivo that calcium
(Ca2+) dynamics are severely altered during SE and that elevations in intracellular Ca2+
([Ca2+]i) in hippocampal neurons are maintained well past the duration of the injury itself
(Ca2+

plateau).

Here we report that similar changes in [Ca2+]i are observed in the

hippocampal neuronal culture model of SE-induced AE. As an important second
messenger, the maintenance of a Ca2+ plateau following injury can lead to several changes
in gene expression, neurotransmitter release, and overall, neuronal plasticity.

Thus,

changes in post-SE [Ca2+]i and Ca2+ homeostasis may be important in understanding
epileptogenesis and eventually preventing the progression to chronic epilepsy.

This

dissertation examines the development and maintenance of the Ca2+ plateau after SE and
demonstrates the novel finding that pharmacological modulation of [Ca2+]i following SE
may inhibit epileptogenesis in vitro.

xix

Chapter 1: General Introduction

Status Epilepticus and Acquired Epilepsy
Epilepsy is one of the most common neurological conditions, affecting about 50 million
people worldwide [1] and approximately 2.7 million Americans [2].

It results in an

estimated annual cost of $15.5 billion [3] and thus, represents a significant clinical
challenge. The condition is characterized by the presence of recurrent, spontaneous
seizures, which stem from sudden neuronal hyperexcitability. Approximately 60% of all
cases of epilepsy are idiopathic, while the remaining 40% occur following neuronal injury
and are thus, classified as acquired. Acquired epilepsy (AE) is a neurological condition
characterized by the development of spontaneous, recurrent seizures following a Central
Nervous System (CNS) injury such as status epilepticus (SE), stroke, or traumatic brain
injury (TBI) [4,5]. The process by which healthy brain tissue is transformed into a
hyperexcitable circuit of neurons giving rise to seizures is called epileptogenesis [6,7].
The focus of these studies will be on AE following SE, as 20-40 percent of all cases of SE
develop this chronic condition [7,8]. Moreover, experimental models of SE-induced AE
remain the most widely studied and best characterized examples of epileptogenesis.
Ultimately, the AE produced in these models closely resembles the pathology observed in
humans and has provided tremendous insight into molecular mechanisms of
1

epileptogenesis. Understanding the pathophysiological mechanisms through which SE
causes the development of AE would lend insight into mechanisms of neuronal plasticity
and also aid in the elucidation of new therapeutic targets to prevent epileptogenesis.

SE has been defined as a medical emergency constituting convulsive or non-convulsive
seizures lasting for at least 30 minutes, or multiple seizures without regaining
consciousness lasting the same duration of time [9,10]. The seizures can be behavioral or
electrographic, which can be determined through electrophysiological monitoring using
electroencephalograms (EEG). This particular definition of SE, as described above, was
reached following reports in experimental animal models that correlated seizure duration
with degree of permanent brain injury; after 30 minutes, animal data indicated significant
declines in brain oxygenation and increases in cardiovascular distress and refractoriness to
treatment.

However, this definition has been revisited because from a treatment

standpoint, after 5 minutes of ongoing seizures there is a high likelihood that the seizure
will continue for at least 30 minutes and become increasingly difficult to treat [11]. In the
United States, the frequency of SE is approximately 100,000-150,000 cases annually with
almost 55,000 deaths per year [12]. Various processes can cause SE including metabolic
disorders, drug toxicity, head trauma, hypoxia, and stroke. Often chronic conditions such
as pre-existing epilepsy, alcohol abuse, or CNS tumors can also precipitate SE [12-15].
Therefore, experimental models are needed to study both SE and SE-induced AE to better
understand mechanisms and develop treatments.

2

Models of SE-Induced AE Provide Important Tools to Study Epileptogenesis
In vivo
There are several different models utilized to study SE-induced AE (Table 1-1). The
development of these models has made SE-induced AE more accessible to study than AE
caused by other brain injuries, such as stroke and TBI. Moreover, models of AE following
SE have provided insight into general mechanisms of neuronal injury [16].
Chemoconvulsants such as pilocarpine and kainic acid, as well as prolonged hippocampal
stimulation leading to the spontaneous development of epileptiform activity, are most
commonly used to induce SE in animals [17,18]. Electrical stimulation can also be used to
trigger SE and is often utilized as a model of epileptogenesis following SE.

The

pilocarpine model has been used most often in the studies described in this dissertation;
thus, in order to understand the model, it is useful to explore the experimental design.
Briefly, rats are injected intra-peritoneally with scopolamine to block the peripheral effects
of pilocarpine, a muscarinic agonist.

30 minutes later, the animals are treated intra-

peritoneally with pilocarpine to trigger SE. The animals are allowed to seize for 1 hr
before the seizures are terminated with a benzodiazepine, diazepam. The animals are
video-EEG monitored approximately 1 month following SE for the development of
recurrent seizures, or epilepsy.

The animal models that utilize chemicals such as pilocarpine follow a progression that
correlates closely with the clinical presentation of SE in man. Following SE-induced brain
injury, there is a latency period characterized by a lack of seizure activity [4,19,20]. This
3

period is then followed by the development of spontaneous, recurrent seizures.

The

progression from SE to AE is thus, often divided into three stages [19,20]: induction or
injury (the episode of SE), a latent period of epileptogenesis, and finally the development
and chronic occurrence of AE (Figure 1-1, Figures from Chapter 1 are adapted from
Nagarkatti et al. [21]). The animal models also share several other characteristics with the
human condition. In the pilocarpine model, similarities including hippocampal neuronal
death, astrocyte proliferation, and microglial activation are observed [18,22]. Although the
in vivo models have the advantage of representing the clinical presentation in an intact
animal, they also provide challenges in studying the mechanisms of epileptogenesis, since
it is difficult to control many of the variables needed to conduct molecular biological
studies in these complex, multi-dimensional systems. Thus, the development of an in vitro
model of epileptogenesis has proven to be a useful addition to understanding this clinical
condition.

In vitro
Our laboratory has developed an in vitro cell culture model of SE and SE-induced AE
using cultured hippocampal neurons plated on glial beds [23].

This model offers a

powerful tool to evaluate potential molecular mechanisms underlying epileptogenesis, but
has the disadvantage of not representing clinical epilepsy in an intact brain. The in vitro
model utilizes a buffer solution with no added magnesium (Mg2+), referred to as “low
Mg2+” to trigger epileptiform discharges, the in vitro correlate to SE. These cultures are
treated with low Mg2+ for three hours (hrs), during which time they manifest continuous
4

epileptiform discharges as a result of removing the Mg2+ block on N-methyl d-aspartate
receptor (NMDAR).

These discharges occur at a frequency greater than three hertz,

consistent with the frequency and characteristics of seizure activity observed in clinical,
electrographic SE.

When the neurons are returned to normal, Mg2+-containing maintenance media and
patched using whole-cell current clamp electrophysiology, they no longer manifest SE-like
continuous epileptiform discharges, the neurons instead show only occasional
depolarizations and short epileptiform discharges. By 12 hrs post-low Mg2+, the neurons
consistently exhibit spontaneous, recurrent epileptiform discharges (SREDs), characterized
by bursts of action potentials over-riding paroxysmal depolarization shifts. At this and all
later time points, between six to nine distinct SRED episodes are observed per hour. These
SREDs meet the electrophysiological characteristics of seizure discharges observed in
patients exhibiting seizure activity. The SREDs persist for the life of the neurons in
culture and are synchronous events between networked neurons. Thus, this model utilizes
an inciting injury that resembles SE to cause the subsequent development of SREDs, an in
vitro correlate to AE. The model exhibits several features consistent with the development
of AE in both in vivo models and the clinical condition, including pharmacoresistance to
anticonvulsants, cell death, homeostatic changes in Ca2+, and spike frequency [23,24].
Moreover, the cell injury observed in the in vitro and in vivo models correspond to that
seen in clinical studies documenting the relationship between SE and neuronal injury [2527].
5

The low Mg2+ in vitro model and the in vivo models of SE-induced AE are useful tools to
study potential molecular mechanisms underlying the induction of AE; however, it is
important to note that there are several limitations in these models. Clear differences
between the experimental models and the human condition include: duration of latency
between SE and the development of epilepsy, percentage of SE cases that develop
epilepsy, and comorbidities associated with the pathology [28].

Yet, despite these

differences, these models have provided much insight on molecular mechanisms of
epileptogenesis and have been useful tools in the elucidation of new therapeutic modalities.

Ca2+ Dynamics in the Rat Pilocarpine Model of SE-Induced AE
Both in vivo and in vitro models of SE-induced AE have provided tremendous insights
into the molecular and cellular changes that occur during and following SE. This research
is important since the characterization of mechanisms that cause AE after brain injuries has
significant implications on the development of new treatments to prevent the progression
to AE. Recently, several studies have highlighted the novel observation that intracellular
Ca2+ ([Ca2+]i) dynamics change during an injury such as SE, stroke, or TBI [29-31].

SE causes elevations in [Ca2+]i
One landmark paper demonstrated changes in hippocampal neuronal Ca2+ during
pilocarpine-induced SE and at various time points post-SE [32]. In brief, rats were treated
with the muscarinic agonist, pilocarpine to induce SE. The SE lasted for 1 hr before being
6

terminated by diazepam, a benzodiazepine. Representative EEG recordings generated
from control animals show ‘normal’ brain activity, whereas traces from animals in SE
demonstrate the high frequency epileptiform discharges observed following treatment with
pilocarpine (Figure 1-2 A). Using this model, it was possible to evaluate hippocampal
neuronal Ca2+ levels during and after SE. Thus, during and immediately following SE, the
rats were sacrificed, hippocampal tissue was acutely isolated, various regions were
dissected out, and neurons were dissociated. [Ca2+]i levels were evaluated in these neurons
using Ca2+ indicator dyes. Significant elevations in [Ca2+]i were observed in hippocampal
neurons from the CA1 region immediately following pilocarpine-induced SE but not in
those isolated from vehicle-control animals, 850±59 nM and 90 ± 22 nM, respectively
(Figure 1-2 B). This represented a 9.4-fold increase in [Ca2+]i between post-SE neurons
and control neurons. These studies suggest that [Ca2+]i, increases during SE.

The Ca2+ plateau following SE: Long-term elevations in [Ca2+]i
This same paper identified the presence of a “Ca2+ plateau” that is maintained well past the
duration of the injury itself in the same rat pilocarpine model of SE-induced AE [32].
[Ca2+]i was evaluated at 1, 2, 6, 10, and 30 days following SE in acutely isolated CA1
hippocampal neurons (Figure 1-3). Neurons from animals in the SE group exhibited
markedly elevated [Ca2+]i at each of these time points. [Ca2+]i does decrease over time
from the levels observed in neurons isolated from animals immediately after SE. By 6
days post-SE, the [Ca2+]i has leveled out but interestingly, is still significantly higher than
concentrations recorded from neurons in the control group.
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More studies are being

conducted to better characterize the Ca2+ plateau in this model so as to aid in our ability to
understand the mechanisms responsible for this novel observation.

SE causes long-term neuroplasticity changes including AE, elevated [Ca2+]i, and
altered Ca2+ homeostatic mechanisms
To determine whether the changes in Ca2+ dynamics were transient or more long-lasting,
animals were treated with pilocarpine or vehicle to induce SE and were then maintained for
one year post-SE [32]. These animals were evaluated for epilepsy using video-EEG and
spontaneous, recurrent seizures were observed only in the pilocarpine group, as shown in
representative EEG recordings from control and epileptic animals (Figure 1-4 A).
Hippocampal neurons isolated from epileptic animals one year post-pilocarpine
demonstrated markedly elevated [Ca2+]i (325 ± 35 nM)—more than double the values
observed in control neurons (Figure 1-4 B).

Neurons from animals displaying the epileptic phenotype were acutely isolated at one-year
post-SE and also challenged with glutamate to evaluate whether homeostatic mechanisms
were intact. Glutamate, as an excitatory neurotransmitter, stimulates neurons so that Ca2+
is released into the cell. Under normal conditions, neurons can recover from this challenge
and restore [Ca2+]i to the concentration observed prior to the stimulation. Neurons from
epileptic animals were unable to restore [Ca2+]i to baseline levels as effectively as control
neurons, therefore suggesting persistent alterations in homeostatic mechanisms at this time
point (Figure 1-4 C). The observation that neurons in animals from the pilocarpine-treated
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group exhibited marked changes in both [Ca2+]i and Ca2+ homeostatic mechanisms one
year after the initial injury suggests that Ca2+ dynamics post-SE affect plasticity changes
and, ultimately, contribute to the maintenance of the chronic, epileptic phenotype.

These studies demonstrated that [Ca2+]i was elevated and Ca2+ homeostatic mechanisms
were altered well past the duration of neuronal injury. These changes appear to play a
significant role in the maintenance of the epileptic phenotype. The elucidation of the
specific mechanisms behind such long-lasting alterations remains an important area of
research; moreover, understanding how these changes lead to development or maintenance
of chronic epilepsy could provide new information for the development of better
treatments or new preventative measures to halt epileptogenesis.

Role of Ca2+ in Normal Cellular Physiology
The importance of altered Ca2+ dynamics is largely based on Ca2+ being an important
divalent, cationic charge carrier that serves as a second messenger in cell signaling [33].
Under standard conditions, extracellular Ca2+ concentration is significantly higher than
intracellular Ca2+ concentration ([Ca2+]i ) at approximately 1-2 mM and 100 nM,
respectively. Regulators of intracellular Ca2+ and of Ca2+ efflux pathways are primarily
responsible for maintaining such low concentrations inside the cell [34].

The large concentration gradient between extracellular and intracellular spaces allows for a
high signal to noise ratio and thus, enables Ca2+ to serve as a second messenger even upon
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the smallest of changes in its intracellular concentration. Transient increases in [Ca2+]i are
required for higher functions such as learning and memory consolidation through the
cellular phenomenon of long-term potentiation (LTP) [35]. In addition, such ephemeral
elevations are necessary for basic neuronal processes, and thereby play a significant role in
synaptic activity and gene expression (Figure 1-5). Moderate to severe injuries can lead to
more sustained elevations in [Ca2+]i resulting in prolonged and often permanent alterations
in cellular function—such increases can overwhelm the cell and regulators of cellular
homeostasis, leading to the initiation of pro-apoptotic pathways and, ultimately, to cell
death [4]. While it is well known that severe elevations in neuronal [Ca2+]i following
injury can lead to both acute and delayed neuronal death [36], studies from our laboratory
have demonstrated that the sustained elevations in [Ca2+]i observed in surviving neurons
lead to altered neuronal function and induce neuronal plasticity [4].

Ca2+, through second messenger effects, can alter gene expression, neurotransmitter
release, basic cellular functions, and plasticity. Thus, it is important to examine the
implications of altered Ca2+ dynamics on the development and maintenance of AE in light
of recent discoveries in this evolving field. Further elucidating how the observed post-SE
Ca2+ plateau contributes both to epileptogenesis and the maintenance of AE remains an
important area of research.

Understanding the mechanisms responsible for the Ca2+

plateau may lead to therapeutic approaches to block this long-term elevation in Ca2+ after
injuries such as SE, therefore leading to the prevention of AE. Thus, learning more about
the mechanisms responsible for altered Ca2+ dynamics after brain injury has potentially
10

important implications for both basic scientists and clinicians. The following presents an
overview of evidence documenting the development of altered Ca2+ dynamics and what is
known on how the Ca2+ plateau following SE contributes to epileptogenesis and AE.

Mechanisms Underlying Ca2+ Changes After SE
Glutamate and NMDA receptors
SE is an excitotoxic injury, meaning it triggers the release of large amounts of the amino
acid neurotransmitter glutamate [37-39]. The degree and duration of SE directly affects
the concentration of glutamate, which has been reported to exist at extracellular
concentrations ranging from 1-5 µM under normal conditions. Excess glutamate following
excitotoxic neuronal injuries such as SE causes the over-stimulation of glutamate
receptors, including the NMDA receptor that is coupled with a Ca2+-permeable ion
channel, thus leading to the excess movement of Ca2+ across the cell membrane into the
cell (Figure 1-6). While glutamate acts at several receptors, it appears that the NMDA
receptor contributes most significantly to the neuronal pathology and to Ca2+ changes
observed post-injury, as confirmed by the ability of NMDA antagonists to offer
neuroprotection when administered prior to injury despite an undiminished SE [40-42].
Several studies have demonstrated that these elevations in glutamate cause neuronal death
and that the inhibition of Ca2+ overload through the use of NMDA antagonists can prevent
both the cognitive sequelae and epileptogenesis [41,43].
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A majority of the work demonstrating that epileptogenesis is Ca2+-dependent was
performed in the hippocampal neuronal culture model of epilepsy as various
pharmacological inhibitors were able to be utilized to tease out which systems were
involved in the process.

One study correlated electrophysiological activity with

intracellular Ca2+ imaging in the presence of various Ca2+ channel inhibitors in order to
determine if any of these channels were contributing to the development of SREDs (Table
1-2) [44]. During the 3 hour low Mg2+ treatment, cells were in the presence of either low
Ca2+ (0.2 mM), 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate (BAPTA) (100µM),
MK-801 (10µM), APV (25µM), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (10µM),
2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) (10µM), or nifedipine
(5µM).

No significant changes in spike frequency, intensity, or epileptic discharge

duration were observed during in vitro SE under each condition [44]. However, both the
Ca2+ chelating agent, BAPTA and the low-Ca2+ conditions prevented the development of
SREDs 48 hrs post-in vitro SE, [44] demonstrating the overall importance of Ca2+ in
causing SREDs. Furthermore, NMDA receptor antagonists, including MK-801 and APV,
exhibited similar effects wherein SE was unaffected but SREDs failed to develop 48 hrs
following low Mg2+[44]. In contrast, the AMPA receptor antagonists CNQX and NBQX,
as well as the antagonist of L-type voltage gated Ca2+ channels, nifedipine, failed to inhibit
SREDs at this time-point [44]. Moreover, when Ca2+ imaging was performed on the
neurons under each condition while the cells were in low Mg2+ it was demonstrated that
only low extracellular Ca2+, NMDA antagonists, and BAPTA were able to prevent or
diminish Ca2+ entry during SE [44]. Thus, this study demonstrated in vitro that Ca2+ is a
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necessary component in the generation of SREDs post-SE and that the NMDA receptor in
particular contributes to the Ca2+ entry involved in epileptogenesis.

Intracellular regulators of Ca2+
Neurons have a network of endoplasmic reticulum (ER) which contributes to the overall
levels of [Ca2+]i by acting to either release or sequester Ca2+ [45]. Ca2+ that is stored in the
ER can be released through activation of the inositol triphosphate receptors (IP3R) or
ryanodine receptors (RyR) [45,46]. These receptors gauge cytoplasmic Ca2+ and mediate
Ca2+-induced Ca2+ release (CICR) from the ER; thus, the channels amplify the Ca2+ signal
coming from outside the cell. IP3 and cyclic ADP ribose, levels of Ca2+ in the ER, and
other messengers can influence the sensitivity of these receptors. The ER also has a
sequestration mechanism through the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA),
which pumps Ca2+ back into the ER from the cytosol [46]. The ER is able to sequester
large amounts of Ca2+ under normal conditions.

Thus, SE causes glutamate release that stimulates Ca2+ entry into the cell, triggering the
activation of CICR wherein RyR and IP3R are activated to release more Ca2+ from ER
stores [47,48]. During the Ca2+ plateau, epileptic neurons show upregulation of CICR
mechanisms when compared to control neurons [48].

Interestingly, one study

demonstrated that the intracellular injection of IP3 causes epileptiform discharges in
hippocampal neurons [49]. Therefore, several groups have examined the ability of antiepileptic drugs to inhibit IP3 or IP3R as a means to prevent epileptiform activity [50,51].
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Moreover, it has also been demonstrated that SERCA is unable to effectively sequester
Ca2+ in “epileptic” neurons, [48] thus suggesting that this mechanism may contribute to the
Ca2+ plateau. Future studies should further examine this relationship between SERCA
uptake and CICR as they are interdependent processes.

Ca2+ binding proteins
Ca2+ binding proteins also play an important role in basic physiology further contributing
to the maintenance of basal [Ca2+]i. It has been hypothesized that the down-regulation of
Ca2+ binding proteins also contributes to the elevated [Ca2+]i maintained during the Ca2+
plateau following SE [52]. Several studies utilizing human epileptic hippocampal tissue
showed that calbindin levels in the dentate granule cells were diminished [53,54]. The
pilocarpine model has yielded similar results wherein it has been demonstrated that at one
month after pilocarpine-induced SE, epileptic animals demonstrated a 50% reduction in
calbindin protein expression in the hippocampus [52]. These changes were observed up to
two years after the initial SE [52]; moreover, calbindin mRNA expression was also
decreased in these animals.

These observations have also been noted a few months post-initial injury in other models
of epilepsy including those utilizing kindling and kainic acid [55,56]. However, some
studies have also shown that following kainic acid or electrically stimulated seizures,
calbindin mRNA levels are unchanged or even increased [57-59]. Therefore, these data
suggest that following a glutamate-induced Ca2+ influx, there is a transient compensatory
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up-regulation in calbindin expression, but the long-term elevations in [Ca2+]i observed in
epileptic animals may be attributed to overall down-regulation in protein expression. This
suggests that the maintenance of the post-SE Ca2+ plateau may be mediated in part by a
decrease in Ca2+ binding proteins, which normally buffer elevations in Ca2+.

Ca2+ regulated enzymes
Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) is an enzyme that plays a
major role in the modulation of neuronal excitability through its actions on Ca2+-dependent
neuronal processes [60,61]. CaM kinase II has a widespread distribution throughout the
nervous system and interestingly, comprises up to 2% of total hippocampal protein [62].

Genetic studies have demonstrated that mice with a null mutation of the alpha-subunit of
CaM kinase II show gene dose-dependent neuronal hyperexcitability and seizures [18]. In
vitro molecular approaches have yielded supporting data by the demonstration that
reduction of α-CaM kinase II levels through antisense oligonucleotides causes spontaneous
epileptic discharges in culture [63]. While these studies have provided tremendous insight
on CaM kinase II as a means of neuronal excitability, they have not examined whether
CaM kinase II expression or activity was actually altered in neurons from epileptic animals
or from cultures exhibiting in vitro epilepsy.

In whole animal and slice models that use repeated hippocampal stimulation to elicit SE,
decreased CaM kinase II activity has been shown to trigger epileptiform activity [64]. Both
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pilocarpine and kainic acid models of SE-induced AE have shown decreased CaM kinase
II activity and these results have also been observed in the low Mg2+ in vitro hippocampal
culture model [65-67]. Interestingly, reduced CaM kinase II activity can be stopped by
NMDA receptor antagonists administered prior to SE [61,67]. Thus, the change in CaM
kinase II activity appears to be a consequence of NMDA receptor activation.
Paradoxically, short-term NMDA receptor activation and the resulting elevations in
intracellular Ca2+ lead to increased CaM kinase II activation and the translocation of the
enzyme from the cytosol to excitatory synapses [68]. The precise role for CaM kinase II in
the induction and development of epilepsy is being actively pursued and several studies
have discussed in great detail the paradoxical nature of its interactions with NMDA
receptors versus the hyperexcitability observed in CaM kinase II knockdown studies [68].
In pentylenetetrazol or electroconvulsive shock studies it has been demonstrated that
seizures cause CaM kinase II to translocate from the synapse to the cytosol [65,69].
Therefore, in distancing the enzyme from its substrate, the translocation may serve to
further reduce the effective enzymatic activity.

Effects of Elevated [Ca2+]i on Cellular Function
Cellular Ca2+ signaling is a complex process that is difficult to elucidate due to the
interdependence of Ca2+ handling/regulatory systems. However, clear links between Ca2+
levels and membrane excitability, protein phosphorylation, and gene regulation have been
demonstrated [70]. Moreover, elevated [Ca2+]i also has a profound effect on the neuronal
circuit, cell death, and glial function. Several studies have demonstrated that this increase
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in Ca2+ concentration triggers hypertrophy of glia and expression of proteins on glia that
are not normally observed [71]. In addition, the elevations in [Ca2+]i have been shown to
activate genes for growth factors, including brain-derived neurotrophic factor and
fibroblast growth factor, induce changes in glutamate receptors, and cause altered
expression of cytoskeletal proteins [71]. All of these alterations significantly affect the
development or maintenance of the epileptic circuit [72].

Developing efficacious

therapeutic strategies may be aided by a more thorough understanding of Ca2+ dynamics in
neurons and how these alterations in Ca2+ can affect glia and the neuronal circuit.

Generally, the degree of Ca2+ influx contributes greatly to the level of injury sustained by
the neurons and impacts the overall fate of the cell. Severely injured cells exhibit an
irreversible Ca2+ overload that leads to cell death through various means, some of which
include: the disruption of cytoskeletal organization, formation of cell membrane blebs,
activation of Ca2+-dependent endonuclease leading to chromatin cleavage, and
mitochondrial impairment resulting in loss of ATP synthesis [73]. Notably, cell death is a
prominent manifestation immediately after SE where [Ca2+]i increases dramatically with a
percentage cell death of approximately 10-15% in vivo [41] and 15% in vitro [24].
Interestingly, epilepsy itself did not cause more cell death in vitro, in vivo, or in human
studies [24,74-78]. Thus, although the elevated Ca2+ plateau is maintained, the levels are
not high enough to induce significant cell death, but can cause permanent alterations in
neuronal homeostasis.
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The neurons that survive SE undergo altered Ca2+ homeostasis but not necessarily an
irreversible Ca2+ overload; therefore, since dead neurons do not seize, it is these injured but
surviving neurons that serve as the substrate for epileptogenesis. These neurons sustain
reversible elevations in [Ca2+]i that are maintained over days or weeks [32]—these
increases mediate changes in synaptic plasticity, gene expression, and neuronal function.
Therefore, the overall increased [Ca2+]i directly affects nuclear Ca2+ levels and leads to the
induction of gene transcription of several pro-apoptotic or epileptogenic genes and alters
neuronal functions including excitability, transmitter release, and neurotoxicity [79]. One
effect is that increases in [Ca2+]i activate an enzyme, calcineurin, leading to a downstream
cascade of events including an accelerated internalization of GABAA receptors, resulting in
decreased inhibitory neurotransmission [18,80]. Thus, it is the injured neurons and these
molecular changes that become potential targets for future therapies to prevent AE. The
ability to target these intracellular changes and reduce the Ca2+ load may prevent the
development of the epileptic phenotype following SE or other neuronal injuries.

Summary and Rationale
Epilepsy is a common condition affecting 1-2% of the world’s population and can
significantly impact an individual’s quality of life. While much progress has been made in
the development of treatments that can inhibit seizures, still approximately 30% of all
people with epilepsy are resistant to anti-convulsant therapies [72,81]. Moreover, 40% of
all cases of epilepsy are acquired following neuronal injury [81]. The development of AE
can be divided into three phases: the injury itself (in this case, SE), followed by a latency
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period during which the neurons are undergoing the changes that lead to the final phase,
the chronic epileptic phase wherein an individual displays recurrent seizures. This
transformation from healthy brain tissue to hyperexcitable neuronal networks responsible
for seizure activity is called epileptogenesis.

Thus, studying the pathophysiological

changes that occur during epileptogenesis could not only bolster our understanding of
plasticity following brain injury but also aid in the development of anti-epileptogenic
agents. Currently, many anti-epileptic drugs (AEDs) exist that inhibit or dampen seizures
in epileptic individuals; however, no therapeutics exist that can be given immediately after
an injury to prevent the ultimate development of epilepsy.

Thus, the latency period

between the injury and the development of AE represents a therapeutic window of
opportunity in preventing epileptogenesis.

Recently, several studies have demonstrated that Ca2+ dynamics are severely altered during
SE and remain altered in those animals that develop AE following SE [4,32]. In the in
vivo rat pilocarpine model of SE-induced AE, [Ca2+]i increases during SE and remains
elevated for at least one year post-SE in those animals that later develop epilepsy [32].
Moreover, hippocampal neurons from epileptic animals also demonstrate persistent
alterations in homeostatic mechanisms, which may contribute to the altered phenotype
[32]. Thus, the modulation of [Ca2+]i and Ca2+ regulatory systems by pharmacological
agents immediately following neuronal injuries such as SE may help to prevent
epileptogenesis.
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The animal model utilized in many of the studies described above, while closely
resembling the human condition, remains a challenging tool to study pharmacological
effects or discern molecular mechanisms because of the difficulties in manipulating the
system and controlling for variables. Therefore, we were interested in testing whether
similar changes as we observed in vivo also occurred in the in vitro low Mg2+ model of
SE-induced AE. If so, this well-characterized model would serve as an ideal tool to better
elucidate molecular mechanisms as well as to perform high throughput screening tests on
various pharmacological compounds.

Central Hypothesis
Studies utilizing the rat pilocarpine model of SE-induced AE have demonstrated that
[Ca2+]i in hippocampal neurons increases during SE, and that these elevations are
maintained only in those animals that go on to develop epilepsy. Ca2+ is an important
second messenger; therefore, changes in its concentration may be responsible for
alterations in cellular function, neurotransmitter release, and, ultimately, neuronal
plasticity.

Therefore, modulation of calcium post-injuries represents an interesting

approach to understanding and potentially preventing epileptogenesis.

Our central

hypothesis is that increases in [Ca2+]i that are triggered by neuronal injury play a role in
mediating epileptogenesis and neuronal plasticity.

To test this hypothesis we have

employed the in vitro low Mg2+ model, as hippocampal neuronal cultures provide an
appropriate model to test both pharmacological and molecular modifications as external
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variables are more easily controlled. In order to address this hypothesis we will focus on
the following aims:
1) Evaluate whether changes in [Ca2+]i observed in the in vivo model of SE-induced AE
are also present in the low Mg2+ hippocampal neuronal culture model
2) Develop pharmacological means to lower [Ca2+]i post-injury (SE)
3) Evaluate whether lowering [Ca2+]i can prevent the expression of spontaneous recurrent
epileptiform discharges, the in vitro correlate to epilepsy
The conclusions reached from this dissertation demonstrate that similar alterations in
[Ca2+]i are observed in the low Mg2+ model as were demonstrated in vivo. Various
pharmacological agents have been tested to determine both which Ca2+ regulatory systems
are contributing to the Ca2+ plateau and whether overall lowering Ca2+ can inhibit
epileptogenesis in the in vitro model of SE-induced AE.
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Table 1-1. Models of SE-induced AE.
In Vitro Models
Hippocampal
Neuronal Culture
In Vivo Models
Rat/Mouse
Chemical:

Electrical:

Inciting Agent

Name of Model

3 hr treatment with
low Mg2+ containing
solution to mimic SE

Low Mg2+ model

SE induced by
treatment with
pilocarpine

Pilocarpine model

SE induced by
treatment with kainic
acid

Kainic acid model

SE induced by
electrical stimulation

Electrical stimulation
model
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Figure 1-1. The progression to AE: Phases of epileptogenesis.
Injuries to the Central Nervous system such as SE (down arrow) can elicit
permanent changes in neurons, resulting in the development of epilepsy. The
period between the inciting injury (down arrow) and the manifestation of
recurrent seizures or epilepsy (black) is called epileptogenesis (gray). This
gray period may provide a therapeutic window of opportunity wherein the use
of pharmacological agents or molecular tools can prevent the transition of
healthy brain tissue to a hyperexcitable network manifesting spontaneous
recurrent epileptiform discharges.
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Figure 1-2. SE causes increased [Ca2+]i acutely in the in vivo pilocarpine model.
A, representative EEG recording from control (vehicle) rats and rats in pilocarpineinduced SE. B, bar graph demonstrating that [Ca2+]i is higher in neurons from
animals immediately following SE when compared to those from animals in the
control group—850 ± 59 nM and 90 ± 22 nM, respectively (data expressed as mean
± SEM).
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Figure 1-3. The Ca2+ plateau following SE. At one day post-SE, [Ca2+]i are
significantly elevated when compared to controls, 790 ± 43 nM and 98 ± 10
nM, respectively (all data expressed as mean ± SEM). Two days post-SE the
[Ca2+]i is 684 ± 47 nM, which is significantly higher than the 96 ± 14 nM
observed in the control. At six days following SE, the [Ca2+]i is still markedly
elevated when compared to controls yet has fallen slightly from earlier
timepoints, 475 ± 36 nM and 100 ± 10 nM, respectively. [Ca2+]i falls slightly
at 10 days post-SE to 395 ± 56 nM but is still significantly elevated when
compared to the controls with [Ca2+]i of 95 ± 14 nM. Finally, at 30 days postSE the [Ca2+]i is 361 ± 28 nM versus 106 ± 16 nM in controls. The persistent
elevation in [Ca2+]i represents the Ca2+ plateau.
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Figure 1-4. AE is associated with alterations in [Ca2+]i and Ca2+
homeostatic mechanisms one year post-in vivo SE. A, representative
EEG recording from control (vehicle) rats and epileptic rats (following
pilocarpine-induced SE). B, bar graph with neurons from epileptic
animals at one year post-SE demonstrating [Ca2+]i of 325 ± 35 nM (data
represented as mean ± SEM), which is significantly higher than neurons
from control group. C, upon glutamate stimulation, the [Ca2+]i increases
and then returns to baseline in neurons from the control group, unlike
neurons from the epileptic group which also peak but then fail to return
to baseline.
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Figure 1-5. Effect of elevated [Ca2+]i on neurons. Normal stimuli cause
transient elevations in [Ca2+]i that control synaptic activity and are
responsible for learning and memory (top arrow). Mild to moderate injuries
may cause prolonged elevations in [Ca2+]i that are ultimately reversible
(middle arrow). Such elevations are not substantial enough to initiate cell
death but are able to cause plasticity changes in neurons, leading to
epileptogenesis. Finally, severe injury causes sustained, massive increases in
[Ca2+]i that lead to cell death (bottom arrow).
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Figure 1-6. CNS injuries cause death or plasticity changes in
neurons. CNS injuries such as stroke, SE, and TBI can lead to one of
two fates for affected neurons. First, all injuries cause increases in
glutamate concentration, which leads to the over-stimulation of
glutamatergic receptors, including NMDA receptors (NMDAR). The
activation of these receptors trigger an influx of Ca2+ across the cell
membrane and cause a Ca2+ overload. This elevation in [Ca2+]i can be
irreversible and overwhelm cellular processes, resulting in cell death. In
contrast, neurons that are less severely injured exhibit a sustained but
reversible increase in [Ca2+]i that leads to alterations in gene
expression, neuronal function, and synaptic plasticity through second
messenger systems.
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Table 1-2. Effect of Ca2+ Inhibitors on SE and SREDs. The first
column shows the various conditions including control and low Mg2+
treated neurons as well low Mg2+ neurons that were then treated with Ca2+
channel inhibitors. The second column shows [Ca2+]i levels observed in
each condition. The third and fourth columns show whether or not the
neurons developed SREDs (epilepsy) or whether the frequency of SE was
changed under each condition, respectively. Data is represented as mean ±
SEM for [Ca2+]i and SE spike frequency and as all or none effects for the
development of epilepsy.
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Chapter 2: Characterization of the Calcium Plateau In Vitro

Introduction
It has been demonstrated in the in vivo pilocarpine model of SE-induced AE that Ca2+
dynamics are significantly altered during SE and that these alterations are maintained well
past the duration of the injury itself [4,32]. As an important second messenger that is
highly regulated so as to maintain low intracellular levels, such alterations could have
tremendous implications in terms of plasticity and ultimately, in the development of
epilepsy following SE. One study published the novel finding that intracellular Ca2+
([Ca2+]i) is elevated almost 8-fold in hippocampal neurons acutely isolated from animals
immediately following SE when compared to those isolated from controls [32].
Interestingly, this elevation exists in hippocampal neurons, particularly those from the
Cornu Ammonis area 1 (CA1) region, but not in frontal or occipital neurons. This result
corresponds to the well-recognized observation that the hippocampus is often most
vulnerable to seizure activity [82] and likely to exhibit increased plasticity changes
following injury. Moreover, this same study evaluated [Ca2+]i at various time points postSE to determine whether the elevations observed acutely were more long-lasting or
ephemeral. It was demonstrated that [Ca2+]i falls gradually over the course of the week
following SE. However, at all latter time points (days 6, 10, 30, and 1 year) post-SE, the
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[Ca2+]i remains significantly elevated when compared to levels recorded in neurons from
either control animals or those animals that fail to develop AE following SE [32]. This
study suggests that SE causes elevations in [Ca2+]i and these sustained elevations may be
involved in the pathophysiology of epileptogenesis. Therefore, it follows that modulation
or inhibition of [Ca2+]i immediately after SE, may potentially prevent the development of
AE.

However, since the precise mechanisms through which increased [Ca2+]i are

maintained following SE remain unclear, it would be beneficial to study the
pathophysiologic changes in an in vitro model wherein the system is more easily
manipulated through molecular biological or pharmacological means.

The purpose of this study is to evaluate [Ca2+]i in an in vitro model of SE-induced AE to
determine if the changes observed in vivo also occur in this model. If so, the model would
be a tremendous tool in the evaluation of new therapeutic modalities aimed at restoring
Ca2+ homeostasis post-injury. The hippocampal neuronal culture model of SE-induced AE
is a well-characterized model that utilizes a solution with no added Mg2+ (low-Mg2+) to
simulate SE [23]. Once the Mg2+ is restored to these cultures and the cells are later
evaluated by whole-cell current clamp electrophysiology, spontaneous, recurrent
epileptiform discharges (SREDs) are observed for their life in culture. These SREDs are
the in vitro correlate to epilepsy. The hippocampal neuronal culture model is an excellent
in vitro model in that it closely corresponds to the human condition in several ways. The
spike frequency of epileptiform discharges during in vitro SE is greater than 3 Hz, which
meets the clinical definition of SE [83]. Moreover, the in vitro SREDs manifested in this
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culture model mimic the electrographic features observed in epilepsy. Due to similarities
between the human condition and this model, the model has been employed to characterize
electrophysiological,

cellular,

epileptogenesis [4,67,83].

and

molecular

mechanisms

underlying

SE

and

Similarities in pharmacoresistance, changes in biochemical

markers, and cell death have also been demonstrated between the clinical condition and
both in vivo and in vitro models [24,84]. Thus, the hippocampal neuronal culture model
provides a useful tool to evaluate changes in Ca2+ dynamics post-in vitro SE.

Materials and Methods
Hippocampal neuronal culture preparation
Hippocampal tissue was harvested from 2-day postnatal Sprague-Dawley rats (Harlan,
Indianapolis,

IN)

in

phosphate

buffered

saline

(PBS)

with

sucrose,

N-[2-

Hydroethyl]piperazine-N’[2-ethanesulfonic acid] (HEPES), and penicillin (10,000
units/mL) but no added Ca2+ or Mg2+. The dissection PBS was maintained at 4◦ and the
dissection itself was performed at room temperature. Hippocampal tissue was separated
from vasculature and meninges under a dissection microscope and was subjected to 0.25%
trypsin at 37°C for 30 minutes, followed by mechanical trituration using fire-polished
Pasteur pipettes.

Cells were counted on a hemocytometer (Scientific Apparatus,

Philadelphia, PA) using the trypan blue dye exclusion method to estimate the concentration
of cells in suspension. The single cell suspension was diluted to a concentration of 1x105
cells/mL in either glial feed (minimal essential media (MEM) with Earle’s Salts
(Invitrogen, Carlsbad, CA), 25 mM HEPES, 2 mM L-glutamine, 3 mM glucose, and 10%
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fetal bovine serum (FBS)) or neuronal feed (MEM with Earle’s Salts, 25 mM HEPES, 2
mM L-glutamine, 3 mM glucose, 100 µg/ml transferrin, 5 µg/mL insulin, 100 µM
putrescine, 3 nM sodium selenite, 200 nM progesterone, 1 mM sodium pyruvate, 0.1%
ovalbumin, 0.2 ng/mL triiodothyroxine, and 0.4 ng/mL corticosterone) supplemented with
5% horse serum (HS).

To grow glial cultures, 1x105 or 5x104 cells in glial feed were plated onto 35 mm plastic
culture dishes or Lab-Tek 2-well glass chambers (Nunc, Naperville, IL), respectively, that
were previously coated with 0.05 mg/ml poly-L-lysine. The cultures were maintained at
37°C in a 5% CO2/95% O2 atmosphere and culture media was replaced three times per
week with fresh glial feed. The glia were grown until confluent and were then treated with
5 µM cytosine arabinoside for two days to halt cell division. On the 10th day in vitro
(DIV), the culture media was replaced with glial feed supplemented with 5% HS instead of
FBS. Then, on the 13th DIV, the glial feed supplemented with HS was replaced with
neuronal feed supplemented with 5% HS.

On the 14th DIV, cells (8.75x104 for glass slides; 2x105 for 35 mm culture dishes)
suspended in neuronal feed plus 5% HS were plated onto the confluent glial beds.
Cultures were maintained under standard conditions at 37°C in a 5% CO2/95% air
atmosphere and were fed twice weekly with neuronal feed containing 20% conditioned
media. Neurons were allowed to mature and all experiments were performed 14-18 days
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following plating of neurons to allow formation of networks, adequate neuronal
maturation, and development of NMDA receptors.

Whole-cell current clamp electrophysiology
Hippocampal neuronal cultures were transferred to the temperature-controlled stages of
either a Nikon Diaphot inverted microscope (Garden City, NY) or Olympus IX-70
(Olympus, Center Valley, PA) in order to perform electrophysiological recordings. A
Flaming-Brown P-80C electrode puller (Sutter Instruments, Sarasota, FL) was utilized to
pull patch microelectrodes from thin borosilicate glass capillaries (World Precision
Instruments, Inc., Sarasota, FL). Only microelectrodes with a resistance of 3-7 MΩ were
used to patch cells. These microelectrodes were filled with an internal solution consisting
of (in mM): 140 K+ gluconate, 1 MgCl2, 10 HEPES, 1.1 ethylene glycol tetraacetic acid
(EGTA), adjusted to pH 7.2, 310 mOsm.

An Axopatch 200A amplifier or an Axoclamp-2A amplifier (Axon Instruments, Foster
City, CA) in current clamp mode was used to obtain recordings from phase-bright
pyramidal-shaped neurons.

The filled microelectrode was secured to the amplifier

headstage and moved using the course-manipulators until the tip is above the neuron to be
patched. Offset potentials were nulled and fine-adjustment manipulators were then used to
position and lower the microelectrode so that it made contact with the surface of the
neuron of interest. Negative pressure was gently applied through the microelectrode to
form a giga-ohm seal and rupture the membrane in the microelectrode tip. Compensation
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for capacitance was performed and recording was initiated. Together, the Neuro-corder
DR-890 (Neurodata Instruments Corp, New York, NY) and Sony Videocassette Recorder
allowed for digitization and storage of data on videocassettes. Acquired data were then
analyzed by playing recordings back through a Dash IV chart recorder (Astro-Med Inc.,
Warwick, RI) or to a computer via a Digidata 1322A (Axon Instruments, Foster City, CA).
Perfusions of drugs into the system were performed using a six-valve perfusion system
(Warner Instrument Corp., Hamden, CT) at a rate of 1 mL/minute.

Calcium microfluorometry
To determine [Ca2+]i in hippocampal neuronal cultures, cells were loaded with Fura-2acetoxymethyl ester (AM) (Molecular Probes, Eugene, OR), a high affinity (Kd=145nM)
Ca2+ indicator dye. Fura-2AM is able to cross cell membranes and once inside the cell, the
AM groups are cleaved by intracellular esterases leaving the cell-impermeant Fura-2 inside
the cell. Once the dye binds to Ca2+, Fura-2 exhibits an absorption shift that can be
observed by exciting the dye at 340 nm instead of 380 nm, the excitation wavelength used
to measure unbound Fura-2. The emission generated by either of these wavelengths can be
measured at 510 nm. Therefore, alternating excitation wavelengths of 340 nm and 380 nm
are utilized to quantify the relative concentration of Ca2+-bound Fura-2 and Ca2+-free Fura2.

Thus, the resulting 340/380 ratio recorded corresponds directly to the total

concentration of Ca2+ inside the cell and can be used to determine changes in [Ca2+]i.
Moreover, the utilization of the 340/380 ratio is important in that it accounts for potential
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confounders such as unequal loading for Fura-2 or variable cell thickness from interfering
with the measurements.

Hippocampal neuronal cultures were loaded with 1µM Fura-2AM dissolved in 0.1%
dimethyl sulfoxide (DMSO) and incubated at 37˚C in 5% CO2/95% air for 30 min. The
cultures were then washed so as to terminate dye-loading. Following the wash, the cells
incubated for another 15 minutes to maximize cleavage of the AM moiety by intracellular
esterases. The cultures were then transferred a heated stage (Harvard Apparatus, Holliston,
MA) wherein the temperature of the cultures could be maintained at 37°C. Pyramidal,
phase-bright neurons were visualized through the 20X, 0.7 numerical aperture fluorite
water immersion objective on an Olympus IX-70 inverted microscope. The Fura-2 was
excited by alternating excitation wavelengths of 340 nm and 380 nm, created through
filtering light from a 75 W xenon arc lamp through optical filters on a Lambda 10-2 wheel
(Sutter Instruments Co., Novato, CA). Emissions were captured at 510 nm through a 400
nm dichroic mirror in a Fura filter cube (Olympus, Center Valley, PA) by using a
Hamamatsu ORCA-ER digital, charged-coupled device (CCD) camera (Hamamatsu,
Bridgewater, NJ).

This system is connected to the fluorescent imaging software,

MetaFluor (Olympus, Center Valley, PA), which allows for image acquisition and
analysis. Images were acquired from any given field at various time intervals depending
on the specific experiment and background fluorescence was subtracted from all acquired
data by imaging hippocampal neuronal cultures that were not loaded with Fura-2. Ratio
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values can be converted to [Ca2+]i using calibration curves described [85] or can be left as
ratio values, which correlate directly with [Ca2+]i .

In vitro SE and SREDs in hippocampal neuronal cultures
In vitro SE was generated using the low Mg2+ model [18] that was developed in the
DeLorenzo lab. Maintenance media (neuronal feed plus conditioned media) was removed
from the hippocampal neuronal cultures and replaced with physiological basal recording
solution (pBRS) consisting of: 145 mM NaCl, 2.5 mM KCl, 10 mM HEPES, 10 mM
glucose, 2 mM CaCl2, 1 mM MgCl2, 0.002 mM glycine, adjusted to pH 7.3, 325 mOsm or
pBRS without the MgCl2 (hereafter referred to as, low Mg2+). The cells then incubated at
37 °C under 5% CO2/95% air atmosphere for 3 hours (hrs). During this time, neurons
were patched using whole-cell current clamp electrophysiology to determine whether cells
in low Mg2+ demonstrated high frequency spiking of greater than 3 Hertz (Hz) in
frequency, which is characterized as the in vitro correlate to SE. The neurons treated with
pBRS served as the controls for the low Mg2+-treated group.

After 3 hrs of low Mg2+ or pBRS treatment, the cells were returned to normal, Mg2+containing maintenance media and were evaluated using whole-cell current clamp
electrophysiology at least 12 hrs post-in vitro SE to determine expression of in vitro
epilepsy, or SREDs. SREDs are characterized by bursts of action potentials over-riding
paroxysmal depolarization shifts. The 3 hr treatment duration was determined after it was
demonstrated that 1 and 2 hrs of low Mg2+ exposure did not produce consistent
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epileptogenecity [23]; whereas, following 3 hrs, greater than 95% of all neurons sampled
expressed permanent alterations in excitability. Interestingly, a 4 hr exposure produced
more extensive cell death, leading to greater variability in the results, as network
connectivity is important in the development of SREDs [23].

Glutamate challenge: Assessing Ca2+ homeostatic mechanisms
In order to assess Ca2+ homeostatic mechanisms, neurons were loaded with Fura-2AM and
challenged with 50 µM glutamate for 2 minutes. After this time, the cultures were washed
with pBRS to remove the glutamate. 340/380 ratio images were captured every 30 seconds
to record both the response to and recovery from glutamate exposure.

Statistical analysis
To determine statistical significance of Ca2+ imaging data, a one-way Analysis of Variance
(ANOVA) test was employed, followed by Fisher’s post-hoc test when appropriate. A pvalue<0.05 was considered statistically significant. Statistical analysis will be performed
using SigmaStat 3.0 or SigmaPlot (Systat Software, San Jose, CA).

Results
In order to determine if the in vitro model of SE-induced AE resembles the in vivo
pilocarpine model in terms of changes in [Ca2+]i, neurons were treated with low Mg2+ and
then evaluated at various time points through both whole-cell current clamp
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electrophysiology to determine activity as well as calcium imaging to quantify changes in
Ca2+.

Treatment of hippocampal neuronal cultures with low Mg2+ causes in vitro SE
Similarly to previous results published by our laboratory [23], replacing neuronal
maintenance media with low Mg2+ produced continuous, high frequency epileptiform
activity consistent with SE (Figure 2-1 B). This frequency of epileptiform discharges was
recorded to be greater than 3 Hz, which is in accordance with the frequency of SE
discharges observed in humans.

The high frequency discharges were observed

immediately after replacing the maintenance media with the low Mg2+ solution and were
quickly abolished (within ~1 min) upon restoration of MgCl2. This activity observed in
neurons treated with low Mg2+ was in contrast to control neurons that were treated with
Mg2+-containing pBRS. These control neurons showed only occasional action potentials
(Figure 2-1 A), consistent with the activity observed in naïve neurons.

In vitro SE causes a significant elevation in [Ca2+]i
While the neurons were still in low Mg2+, the cultures were loaded with the Ca2+ indicator,
Fura-2AM.

Fluorescent ratio values were obtained using alternating excitation

wavelengths of 340 nm and 380 nm. The resulting 340/380 ratios correspond directly to
[Ca2+]i. Moreover, pseudocolor images were generated wherein individual pixels from the
captured image are assigned a color based on the associated grayscale values, which
correspond to Ca2+ levels. Red is associated with a higher grayscale value and thus, more
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Ca2+; whereas, at the other end of the colorimetric spectrum, blue is associated with lower
grayscale values and less Ca2+. Pseudocolor allows for better visualization of changes in
[Ca2+]i. An increase from control, baseline [Ca2+]i was observed while the neurons were in
the low Mg2+ solution (in vitro SE). The Fura-2 340/380 ratios increased from 0.39±0.05
in control neurons to 0.78±0.05 in neurons after 3 hrs of low Mg2+ (Figure 2-2 A).
Pseudocolor images confirmed these changes in Fura-2 ratios with increased ratios in
neurons post-low Mg2+ (Figure 2-2 B, right panel) but not in the sham controls (Figure 2-2
B, left panel).

Previous studies have shown with high speed simultaneous

electrophysiological and Ca2+ imaging that each epileptiform spike was associated with
increases in [Ca2+]i.

Three hours of low Mg2+ treatment leads to the development of in vitro epilepsy
(SREDs)
To evaluate Ca2+ dynamics following SE, cultured hippocampal neurons were patchclamped to study electrophysiological activity and also imaged for evidence of alterations
in Fura-2 ratios 24 hrs post-low Mg2+ treatment [23,86]. When patched using whole-cell
current clamp techniques, the low-Mg2+ treated cells consistently displayed SREDs (Figure
2-3 B) unlike the sham-control neurons, which failed to show SREDs (Figure 2-3 A).
Each event was spontaneous and on average, 8 events were observed per hour.

In

accordance with previous studies in our lab, most SREDs lasted for ~30 sec with some
extending for 1-2 min in duration [23]. These SREDs recorded in cultures that were
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treated with low Mg2+ resembled what is generally observed in clinical epilepsy, with the
in vitro seizure episodes consisting of paroxysmal depolarization shifts.

Elevations in [Ca2+]i are maintained for at least 24 hours post-in vitro SE
At the same time time-point upon which neurons were patched to look for SREDs, neurons
were also loaded with Fura-2 to determine [Ca2+]i. In brief, hippocampal neuronal cultures
were treated with low Mg2+ for 3 hrs, returned to Mg2+-containing maintenance media, and
then loaded with Fura-2 24 hrs post-in vitro SE. 340/380 ratios were recorded as a direct
indicator of [Ca2+]i. Ratio values in low Mg 2+ treated cells appeared significantly elevated
when compared to control neurons even at 24 hrs post-in vitro SE. This was indicated by
an increase in Fura-2 340/380 ratios from 0.40±0.02 in control neurons to 0.46±0.02 in low
Mg2+ neurons (Figure 2-4).

Neurons displaying SREDs exhibit alterations in Ca2+ homeostatic mechanisms
In addition, SE caused permanent changes in plasticity as demonstrated by alterations in
Ca2+ homeostatic mechanisms. Neurons were briefly stimulated with 50µM glutamate for
2 minutes to test the ability of Ca2+ homeostatic mechanisms to compensate for brief
excitatory challenges. These cells demonstrated a markedly diminished ability to recover
from the insult (Figure 2-5) suggesting that the homeostatic mechanisms, which under
normal conditions maintain tight control of Ca2+ influx, efflux, and sequestration are
altered or diminished following SE. Stimulation with glutamate resulted in an increase in
[Ca2+]i both in control and post-SE neurons; however, in neurons treated with low Mg2+,
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Ca2+ never returned to basal levels and showed a decreased rate of recovery when
compared to controls.

Discussion
These results demonstrate that the low Mg2+ hippocampal neuronal culture model of SEinduced AE may prove to be a useful tool in studying epileptogenesis. The in vitro SE that
was produced resembled the human condition in spike frequency and the model
reproducibly caused SREDs, the in vitro correlate to epilepsy.

Finally, and most

interestingly, several pathophysiological features observed in the rat pilocarpine model of
SE-induced AE also exist in this culture model, making it a useful tool to better understand
molecular/cellular changes and develop new therapeutics before testing in the animal
model. We demonstrated in this study that, much like the in vivo model, increases in
[Ca2+]i were observed during SE and that these elevations were maintained for at least 24
hrs post-SE.

Moreover, as observed in hippocampal neurons acutely isolated from

epileptic animals, cultured neurons that displayed SREDs also showed a decreased ability
to recover from a glutamate challenge. This suggests that epilepsy alters Ca2+ homeostatic
mechanisms and that this may contribute either to the development or maintenance of the
chronic epileptic phenotype.

These studies demonstrated that well past the duration of in vitro SE, [Ca2+]i was elevated
and Ca2+ homeostatic mechanisms were altered in the low Mg2+ culture model of SEinduced AE. In the in vivo model wherein approximately 2/3 of the animals develop
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epilepsy following SE, only the animals that have increased hippocampal [Ca2+]i develop
epilepsy [32]. This finding suggests that the changes in Ca2+ appear to play a significant
role in the maintenance of the epileptic phenotype.

Moreover, it has also been

demonstrated in stroke-induced epileptogenesis that increases in [Ca2+]i are not simply
triggered by the seizure activity itself, because in vitro treatment of neurons showing
SREDs with tetradotoxin to block all action potentials does not completely inhibit the
elevation in [Ca2+]i [87]. The elucidation of the specific mechanisms behind such longlasting alterations remains an important area of research; moreover, understanding how
these changes lead to the development or maintenance of chronic epilepsy could provide
new information for the design of efficacious treatments or new preventative measures to
halt epileptogenesis.

In the pilocarpine model of SE-induced AE, it is well established that the elevations in
[Ca2+]i are maintained post-injury in animals that develop epilepsy.

However, other

conditions including stroke and TBI can also lead to the development of epilepsy. Finding
common pathophysiologic mechanisms behind how excitotoxic injuries can lead to the
epileptic condition will bolster efforts to design new therapeutics to prevent
epileptogenesis.

Thus, the examination of Ca2+ dynamics in other models of injury-

induced epilepsy may be of great clinical importance and represent an important area to
study in the future. As a ubiquitous second messenger, alterations in [Ca2+]i and Ca2+
homeostatic

mechanisms

have

significant

repercussions

on

gene

expression,

neurotransmitter release, and hence, neuronal plasticity. Therefore, the development and
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use of myriad models of acquired epilepsy to better understand the relationship between
Ca2+ and epileptogenesis may offer an important tool in the future.

It should be noted that the modulation of [Ca2+]i is a challenging pursuit in that Ca2+ is a
ubiquitous second messenger that affects everything from neurotransmission to gene
expression and has important functions in most cells of the body.

This means that

modulation of Ca2+ has the potential to cause many unwanted side effects until more
specific methods of drug delivery/Ca2+ targeting are developed. Despite these difficulties
in the modulation of Ca2+, many studies have utilized Ca2+ channel antagonists or Ca2+chelating agents with varying degrees of success. Perhaps the most promising study is a
Phase II clinical trial that utilized DP-BAPTA, a Ca2+-chelating agent, to patients
following stroke and found that this treatment did not cause vascular or neurological side
effects, but did improve the National Institutes of Health stroke scores [88]. Moreover,
patients with Alzheimer’s disease are being treated with the NMDA antagonist,
Memantine, which affects Ca2+ influx into the cell [89].

Despite these cases wherein Ca2+-modifying agents have been used to improve outcomes
from various neurological pathologies without significant deleterious effects, there is both
positive and negative data regarding whether or not Ca2+ channel antagonists can be used
as anti-convulsants or to potentiate the effects of other AEDs [90,91]. However, a good
AED does not necessarily exhibit anti-epileptogenic properties and very little work has
explored whether Ca2+-modifying agents can affect epileptogenesis. The few studies that
45

exist have predominately used the NMDA antagonist, MK-801. One study demonstrated
that this drug could effectively decrease the number of animals that developed epilepsy
following electrically-stimulated SE [43], while another study showed that in the kainic
acid model of SE-induced AE, MK-801 did not prevent the development of epilepsy [92].
Such conflicting results between models have underscored the need for many different
types of models to be utilized [93] and have demonstrated that common pathophysiologic
features need to be understood so as to develop better targets for anti-epileptogenic agents.
Thus, the in vitro hippocampal neuronal culture model provides a useful tool in
preliminary tests to determine anti-epileptogenic effects prior to screening in more
complex systems.

Moreover, the presence of these alterations in [Ca2+]i and Ca2+

homeostatic mechanisms in both the pilocarpine and low Mg2+ model suggest that these
may be common pathophysiologic features of epileptogenesis; therefore, understanding
these changes may aid in the development of anti-epileptogenic agents.
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Figure 2-1. Treatment of hippocampal neuronal cultures with low
Mg2+ causes in vitro SE. A, representative whole-cell current-clamp
electrophysiological recordings obtained from a control neuron and B,
a neuron in low Mg2+, or in vitro SE. The neuron in low Mg2+ shows
epileptiform discharges at a frequency greater than 3 Hertz. In contrast,
the control neuron shows action potentials intermittently, consistent
with baseline firing activity. Resting membrane potential= -62 mV;
duration of trace shown= 18 min.
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Figure 2-2. In vitro SE causes a significant elevation in [Ca2+]i. A, bar
graph comparing Fura-2 340/380 ratios in control neurons versus neurons
immediately following 3 hrs of low Mg2+. The low Mg2+-treated cells
exhibit ratio values of 0.78±0.05 as compared to the control neurons with
values of 0.39±0.01 (data expressed as mean ± SEM). B, representative
pseudocolor ratio images obtained from control (left panel) and low Mg2+treated (right panel) neurons. Neurons from the low Mg2+ group show an
increased 340/380 ratio immediately following treatment.
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Figure 2-3. Low Mg2+ treatment leads to the development of in vitro
epilepsy (SREDs). A, electrophysiological traces using current-clamp
technique demonstrate baseline activity in control neurons and B, spontaneous,
recurrent epileptiform discharges (SREDs) in neurons that had been treated in
low Mg2+ for 3 hrs and then returned to normal maintenance media. Resting
membrane potential= -61.5 mV; duration of shown trace= 30 min.
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Figure 2-4. Elevations in [Ca2+]i are maintained for at least
24 hours post-in vitro SE. Bar graph comparing 340/380 ratio
values in control versus SE groups 24 hrs after treatment with
Mg2+-containing buffer solution or low Mg2+, respectively.
Neurons in the SE group exhibit a 340/380 ratio of 0.46±0.02
(mean ratio ± SEM). The ratio from control group neurons is
significantly lower at 0.40±0.02.
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Figure 2-5. Neurons displaying SREDs exhibit alterations in Ca2+
homeostatic mechanisms.
Glutamate stimulation causes increased
[Ca2+]i. Peak ratios following glutamate are normalized to 1.0. Recovery
from this challenge is hindered in epileptic neurons when compared to
controls.
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Chapter 3: Dantrolene Inhibits the SE-Induced Calcium Plateau and
Prevents the Development of Spontaneous Recurrent Epileptiform
Discharges in Hippocampal Neuronal Cultures

Introduction
Epilepsy is a common neurological condition that is characterized by spontaneous,
recurrent seizures and affects 1-2% of the population worldwide [2,81]. Acquired epilepsy
(AE) is one form of epilepsy that occurs following a brain injury such as status epilepticus
(SE), traumatic brain injury (TBI), stroke, or infections of the central nervous system
(CNS) [4,5]. AE represents approximately 40% of all cases of epilepsy [81]; thus, it
remains an important public health concern. The transformation of healthy brain tissue
into hyperexcitable networks of neurons that manifest epileptiform discharges is called
epileptogenesis. Characterization of this process may help in elucidating particular targets
to which potential anti-epileptogenic agents can be directed. Currently, only anti-epileptic
drugs (AEDs) exist, which limit the occurrence of seizures once an individual has epilepsy.
However, there are no anti-epileptogenic agents to prevent the process of epileptogenesis.
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In order to better understand the process of epileptogenesis, many divide the development
of AE into three stages: the injury itself, a period of latency or epileptogenesis, and finally,
the maintenance of chronic epilepsy [19,20]. The period between the injury and the
development of epilepsy could provide a therapeutic window of opportunity wherein
pharmacological agents could be administered to prevent epileptogenesis.

Thus,

characterization of the pathophysiological changes that occur following neuronal injury is
necessary in order to find new therapeutic targets.

It was demonstrated in the pilocarpine model of SE-induced AE that SE causes significant
changes in [Ca2+]i and Ca2+ homeostatic mechanisms in hippocampal neurons [32]. As far
out as 1 year post-SE, animals that demonstrated epilepsy showed significant elevations in
hippocampal neuronal Ca2+ levels (Ca2+ plateau), in contrast to those animals that failed to
develop epilepsy post-SE [32]. As a ubiquitous second messenger, changes in [Ca2+]i can
affect everything from neurotransmitter release to gene transcription. Therefore, studying
these alterations in Ca2+ and the underlying regulatory systems that control these changes
is important not only in understanding plasticity but also in developing anti-epileptogenic
strategies.

It was also demonstrated in the rat pilocarpine model of SE-induced AE that the N-methylD-aspartic acid (NMDA) antagonist, MK-801, when administered prior to SE, does not
diminish SE but is able to prevent both the Ca2+ plateau as well as, the development of
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epilepsy [32].

This study provided evidence that NMDA receptors (NMDAR) are

involved in initiating the Ca2+ plateau during SE. However, little is known regarding what
systems contribute to the long-term maintenance of these elevations in intracellular Ca2+
([Ca2+]i) and whether inhibiting this elevation after the injury could prevent
epileptogenesis.

We hypothesized that the calcium-induced calcium release (CICR)

system was activated by the massive influx of Ca2+ into the cell through NMDAR.
Ryanodine receptors (RyR), along with inositol triphosphate receptors (IP3R), are part of
the CICR mechanisms and control [Ca2+]i inside of the cell by acting to either release or
sequester Ca2+. These receptors gauge cytoplasmic Ca2+ and mediate CICR from internal
stores; therefore, these channels can either amplify or dampen the Ca2+ signal coming from
outside the cell [45,46]. In these studies, dantrolene, a pharmacological inhibitor of RyR,
was used to better elucidate the role of these receptors in the development of the Ca2+
plateau.

While the rat pilocarpine model has provided a great deal of information regarding
potential pathophysiologic changes that occur during epileptogenesis, the whole-animal
model is far too complex to be useful in preliminary pharmacological screenings. Thus,
this study utilizes the hippocampal neuronal culture model wherein low Mg2+ is used to
induce SE-like activity that leads to the development of spontaneous, recurrent
epileptiform discharges (SREDs), the in vitro correlate to epilepsy. We assessed whether
the changes in [Ca2+]i observed in the rat pilocarpine model also existed in this model. If
such changes existed, this model could provide a useful tool in further characterizing these
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pathophysiological mechanisms behind epileptogenesis in a less complex system.
Furthermore, we examined whether giving the RyR inhibitor, dantrolene, post-in vitro SE
could prevent the development of SREDs.

Materials and Methods
Reagents
All the reagents were purchased from Sigma Chemical Co. (St Louis, MO) unless
otherwise noted. Cell culture media was purchased from Invitrogen (Carlsbad, CA).

Hippocampal neuronal culture preparation
All animal use procedures were in strict accordance with the National Institutes of Health
Guide

for

the

Care

and

Use

of

Laboratory

Animals

and

approved

by

Virginia Commonwealth University's Institutional Animal Care and Use Committee. As
described previously [23], hippocampal neurons were harvested from 2-day postnatal
Sprague-Dawley rats (Harlan, Indianapolis, IN) and grown on a glial support layer that was
previously plated onto poly-L-lysine (0.05 mg/mL) coated plates.

The cultures were

maintained at 37°C in a 5% CO2/95% air atmosphere and neuronal cultures were fed twice
a week with minimal essential media containing: Earle's Salts, 25 mM HEPES, 2 mM lGlutamine, 3 mM Glucose, 100 µg/mL transferrin, 5 µg/mL insulin, 100 µM putrescine, 3
nM sodium selenite, 200 nM progesterone, 1 mM sodium pyruvate, 0.1% ovalbumin, 0.2
ng/mL triiodothyroxine, and 0.4 ng/mL corticosterone supplemented with 20% conditioned
media. Neurons were allowed to mature and all experiments were performed 14-18 days
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following plating of neurons to allow formation of networks, adequate neuronal
maturation, and development of NMDA receptors.

Whole-cell current clamp electrophysiology
Whole-cell current clamp electrophysiology was performed according to previously
described procedures [23,84]. In short, hippocampal neuronal culture media was replaced
with physiological basal recording solution (pBRS) containing (in mM): 145 NaCl,
2.5 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, 10 glucose, and 0.002 glycine, pH 7.3, and
osmolarity adjusted to 325 ± 5 mOsm with sucrose. The plates were transferred to the
temperature-controlled stages of either a Nikon Diaphot inverted microscope (Garden City,
NY) or Olympus IX-70 (Olympus, Center Valley, PA) in order to perform
electrophysiological recordings.

A Flaming-Brown P-80C electrode puller (Sutter

Instruments, Sarasota, FL) was utilized to pull patch microelectrodes with resistances of 37 MΩ from thin borosilicate glass capillaries (World Precision Instruments, Inc., Sarasota,
FL). These microelectrodes were filled with an internal solution consisting of (in mM):
140 K+ gluconate, 1 MgCl2, 10 HEPES, and 1.1 ethylene glycol tetraacetic acid (EGTA),
adjusted to pH 7.2, and osmolarity of 310 mOsm.

An Axopatch 200A amplifier or an Axoclamp-2A amplifier (Axon Instruments, Foster
City, CA) in current clamp mode was used to obtain recordings from phase-bright
pyramidal-shaped neurons. Together, the Neuro-corder DR-890 (Neurodata Instruments
Corp, New York, NY) and Sony Videocassette Recorder allowed for digitization and
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storage of data on videotapes. Acquired data were then analyzed by playing recordings
back through a DC-500 Hz chart recorder (Astro-Med Inc., Warwick, RI) or to a computer
via a Digidata 1322A (Axon Instruments, Foster City, CA).

Calcium microfluorometry
To determine [Ca2+]i in hippocampal neuronal cultures, cells were loaded with 1µM Fura2-acetoxymethyl ester (AM) (Molecular Probes, Eugene, OR) for 30 min at 37˚C in 5%
CO2/95% O2, as described previously [50].

The plates were then transferred a

temperature-controlled stage (Harvard Apparatus, Holliston, MA) on an Olympus IX-70
inverted microscope. Ratio images were acquired using alternating excitation wavelengths
(340 and 380 nm) with a filter wheel (Sutter Instruments, Novato, CA) and fura filter cube
at 510/540 nm emissions with a dichroic mirror at 400 nm [94]. Thus, the resulting
340/380 ratio recorded corresponds directly to the total concentration of Ca2+ inside the cell
and can be used to determine changes in [Ca2+]i. The utilization of the 340/380 ratio is
important in that it accounts for potential confounders such as unequal loading for Fura2AM or variable cell thickness from interfering with the measurements. This system is
connected to the fluorescent imaging software, MetaFluor (Olympus, Center Valley, PA),
which allows for image acquisition and analysis. Images were acquired from any given
field at various time intervals depending on the specific experiment and background
fluorescence was subtracted from all acquired data by imaging hippocampal neuronal
cultures that were not loaded with Fura-2AM.
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In vitro SE and SREDs in hippocampal neuronal cultures
In vitro SE was generated using a low Mg2+-containing solution [18]. Maintenance media
was replaced with low Mg2+ (pBRS without any added MgCl2). The cells then incubated
at 37 °C under 5% CO2/95% O2 atmosphere for 3 hrs. During this time, when the neurons
were patch-clamped using whole-cell current clamp electrophysiology, they demonstrated
high frequency spiking, characterized as in vitro SE. Neurons treated with pBRS for 3 hrs
served as the sham-controls.

After 3 hrs of low Mg2+ or pBRS treatment, the cells were returned to normal, Mg2+containing maintenance media and were evaluated using whole-cell current clamp
electrophysiology at least 12 hrs post-in vitro SE to determine expression of in vitro
epilepsy, or SREDs.

Each episode of SREDs is characterized by paroxysmal

depolarization shifts and generally, 5-9 SREDs are observed per hour.

Cell death assay
Neuronal death was assessed using the dye, Propidium Iodide (PI) as well as, Annexin V
conjugated to fluorescein isothiocyanate (FITC).

PI binds DNA in membrane-

compromised neurons, whereas, Annexin V binds phosphotidylserines that translocate to
the outer cell membrane in the early stages of apoptosis. Several randomly selected fields
from each plate were marked and both phase and fluorescent images were captured using
MetaMorph (Olympus, Center Valley, PA). Fraction of neuronal death was calculated as
the number of neurons labeled with only Annexin V plus the number of neurons labeled
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with Annexin V and PI, divided by the total number of neurons. The data was subjected to
an outlier test wherein all values outside of two standard deviations from the mean were
considered outliers.

Pilocarpine preparation
All animal use procedures were in strict accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by Virginia
Commonwealth University’s Animal Use Committee. Sprague-Dawley rats, weighing
between 185-235 g, were injected intra-peritoneally (i.p.) with the muscarinic agonist,
pilocarpine (375 mg/kg).

20 minutes prior to this injection, the animals were given

methyl-scopolamine nitrate (1mg/kg) i.p. to block the systemic effects of pilocarpine.
Both of these drugs were dissolved in 0.9% saline and filter-sterilized. Behavioral seizures
generally began within 20 minutes of injection with pilocarpine. Animals were allowed to
seize for 1 hr before SE was terminated by the i.p. administration of 4 mg/kg diazepam
(DZP) at 1, 3, and 5 hrs post-SE. Sham animals were injected with all of the drugs
described above except pilocarpine, instead they received equal volumes of 0.9% saline i.p.
When appropriate, animals received either dantrolene (10 mg/kg) or vehicle (DMSO) i.p.
at the end of 1 hr of SE for studies related to epileptogenesis.

Acute isolation of hippocampal neurons
Animals were sacrificed 24 hrs post-SE to determine [Ca2+]i in hippocampal neurons from
the sham, pilo-vehicle, and pilo-dantrolene treated groups. Briefly, as described previously
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[85], hippocampal slices were cut and incubated for 1 hr following dissection in
oxygenated artificial cerebrospinal fluid (aCSF). Slices were exposed to 8 mg/ml Type
XXIII protease (Sigma Chemical Co, St. Louis, MO) for 6 minutes, and then washed to
abolish protease activity. Mechanical dissociation of tissue was accomplished through
trituration in N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer using a
series of fire polished Pasteur pipettes. Dispersed neurons were plated in buffer containing
Fura-2AM onto poly-L-lysine and Cell-Tak (BD Biosciences, Franklin Lakes, NJ) coated
culture dishes allowing the appropriate adherence to conduct [Ca2+]i imaging.

Racine score
To evaluate severity of behavioral seizures during SE, the Racine scoring method was used
[95]. The Racine scale scores various behavioral traits during SE and in doing so, serves
as a quantitative tool to measure seizure severity. The scale rates behaviors on a scale
from 0-6, with 0=no SE to 6=severe tonic-clonic seizures resulting in death.

Isolation and homogenization of hippocampal tissue
At various time points either during or after SE, animals were anesthetized by inhalation of
isoflurane until the righting reflex was lost and respiration rate slowed and were then
rapidly decapitated. The brain was quickly removed and dissected. Hippocampal tissue
was separated from the rest of the brain and flash-frozen in liquid nitrogen. The frozen
hippocampus was homogenized using a motorized homogenizer in 750 µL of modified,
ice-cold RIPA buffer consisting of: 1% NP-40, 10 mM Tris-HCl (pH 7.4), 150 mM
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NaCl, and 1% Triton- X100, as well as, phenylmethanesulphonylfluoride (PMSF), and
Halt Phosphatase Inhibitor Cocktail (Pierce, Rockford, IL) to inhibit protease and
phosphatase activity, respectively. The homogenates were stored at -80°C and protein
concentration was measured using the Bradford reagent (BioRad, Hercules, CA) and a
spectrophotometer (595 nm).

Western blotting
Western blotting of hippocampal homogenates was performed as described previously
[52]. In brief, protein (10 µg /lane) was resolved on SDS-PAGE and transferred to a
polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA) at 100 V, 4°C.
Membranes were blocked using 5% bovine serum albumin (BSA) made up in tris-buffered
saline containing 0.1% Tween-20 (TBST) for 1 hr at room temperature (RT). Primary
antibodies were made up in this 5% BSA solution. The membrane incubated in the RyR2
primary antibody (1:200) (Alamone Labs #ARR-002, Jerusalem, Israel) overnight at 4°C
or phospho-RyR2 (1:5,000, Serine-2809) (Badrilla #P010-30, Leeds, United Kingdom) for
1 hr at RT. To assess whether there was equal loading of protein, blots were cut and
incubated in actin (1:8000) (Chemicon #MAB1501, Billerica, MA) or β-tubulin (1:4000)
(AbCam #ab6046, Cambridge, MA) for 1 hr at RT. The membranes were washed with
TBST 5 times following incubation with primary antibody and incubated for 1 hr with goat
anti-rabbit (1:10,000, for phospho-RyR2, RyR2, β-tubulin antibodies) (Chemicon
#AP132P) or goat anti-mouse (1:10,000, for actin antibody) (Chemicon #AP124P)
secondary antibodies conjugated to horseradish peroxidase. The blots were washed 5
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times with TBST and washed in enhanced chemiluminescence reagent (SuperSignal,
Pierce, Rockford, IL) prior to exposing Kodak X-Omat Blue XB-1 X-ray film (Eastman
Kodak, Rochester, NY) for detection of protein.

Data analyses
Data were expressed as mean ± SEM. To determine significance between treatment groups
for Ca2+ imaging, SREDs, and neuronal death assays, one-way analysis of variance
(ANOVA) tests were employed, followed by Fisher’s post-hoc test when appropriate. For
the Ca2+ imaging and cell death experiments, at least 6 plates were used per treatment
group. For electrophysiology experiments, 2-3 neurons are patch-clamped from each plate
with a minimum of 5 plates used for each treatment group.

All experiments were

performed over the period of several weeks so that the results were representative of
multiple cultures.

A p-value<0.05 was considered statistically significant. Statistical

analysis was performed using StatView 5.0.1 and graphs were drawn using SigmaPlot
(Systat Software, San Jose, CA).

Results
In the rat pilocarpine model of SE-induced AE, hippocampal neuronal [Ca2+]i increases
during SE and significant elevations in [Ca2+]i are maintained for at least one year post-SE
in those animals that go on to develop epilepsy. Thus, our first aim was to evaluate
whether similar long-term changes in [Ca2+]i are observed in the in vitro, low Mg2+ model.
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In vitro SE causes significant, long-lasting elevations in [Ca2+]i (Ca2+ plateau)
Neurons were treated for 3 hrs with either low Mg2+ to simulate in vitro SE or pBRS as a
sham control, in accordance with previously described methodology [23]. The cells were
loaded with the Ca2+ indicator, Fura-2AM to determine 340/380 ratios both at the end of
this treatment and at various time points following the treatment (Figure 3-1). These
fluorescent ratio values were obtained using alternating excitation wavelengths of 340 nm
and 380 nm, and the resulting 340/380 ratios correspond directly to [Ca2+]i. There was no
significant difference in 340/380 ratios between the sham control neurons that were treated
with pBRS at any of the time points tested. In contrast, neurons treated with low Mg2+
displayed ratio values of 0.78±0.05 acutely at the end of this 3 hr treatment, approximately
double the ratio values observed in sham controls.

In order to end in vitro SE, MgCl2 was restored to these cultures by washing them with
pBRS.

The same neurons were imaged for the first hour post-restoration of MgCl2.

Within 10 min of restoring the MgCl2 to the low Mg2+-treated plates, the 340/380 ratio
dropped from 0.78±0.01 to 0.67±0.05. At 30 min post-in vitro SE, the ratios fell slightly to
0.66±0.06 and at 60 min post-SE to 0.60±0.07. At the 3 hr and 6 hr time points, the
340/380 ratios had dropped further to 0.46±0.01 and 0.43±0.01, respectively. Finally, at
24 hrs post-in vitro SE, the low Mg2+-treated cells exhibited 340/380 ratios of 0.46±0.02.
n= 6 plates at each time point tested with 52-134 neurons imaged in total per treatment
group. The recorded ratios in the low Mg2+-treated group were significantly elevated when
compared to the controls at each of the time points tested. This suggests that low Mg2+64

induced in vitro SE triggers long-lasting elevations in [Ca2+]i, as evidenced by maintenance
of increased 340/380 ratios for at least 24 hrs.

Dantrolene lowers [Ca2+]i to baseline levels following in vitro SE
We next wanted to test whether these persistent elevations in [Ca2+]i following low Mg2+induced SE-like activity could be inhibited pharmacologically and whether doing so,
would prevent the expression of SREDs. Dantrolene, an inhibitor of RyR, was utilized
immediately post-in vitro SE to determine whether inhibition of RyR-mediated CICR
could lower the elevated [Ca2+]i. To test this, hippocampal neuronal cultures were treated
for 3 hrs with low Mg2+ and were then loaded with Fura-2AM. As shown in Figure 3-2,
following 3 hrs of in vitro SE (time 0 on x-axis), neurons showed elevations in 340/380
ratios that were normalized to the peak ratio. These neurons were then treated with either
dantrolene (50 µM) or vehicle (0.1% DMSO). At 5 min post-treatment, vehicle-treated
cells showed a slight decrease in 340/380 ratio; in contrast, dantrolene-treated cells
exhibited 340/380 ratios that were 47% of the peak observed at the end of in vitro SE. At
10 min post-treatment, the 340/380 ratio values were 83% and 43% of the post-SE peak in
vehicle- and dantrolene-treated groups, respectively.

At 15 min post-treatment, the

340/380 ratio values were 82% and 40% of the post-SE peak in vehicle- and dantrolenetreated groups, respectively. In the cells that were exposed to dantrolene after the low
Mg2+ treatment, [Ca2+]i returned to the baseline levels observed in the naïve controls (data
not shown) within 20 minutes. In contrast, the vehicle controls showed elevated [Ca2+]i at
all time points tested—the 340/380 ratios fell by only 18% over the first 20 minutes
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following in vitro SE, consistent with the data reported in Figure 3-1. There was a
significant difference in the 340/380 ratios between the dantrolene and vehicle treated
groups at each time point after 1 min of treatment, with the dantrolene-treated group
showing marked enhancement in the ability to rapidly lower the [Ca2+]i. n=6 plates were
used per treatment group with ~60 neurons imaged in total per condition. These
experiments demonstrated that dantrolene was able to lower [Ca2+]i when administered
acutely after in vitro SE; thus, suggesting that RyR may play a role in mediating the postSE elevations in [Ca2+]i.

In vitro SE is not inhibited by dantrolene
This in vitro hippocampal neuronal culture model of SE is, much like the clinical
condition, difficult to treat because it is highly refractory to anticonvulsant treatment.
Thus, we sought to determine if dantrolene could act to block this low Mg2+-induced, high
frequency spiking. Using whole-cell current clamp electrophysiology, we observed that
naïve cultured hippocampal neurons exhibited infrequent spontaneous action potentials
while in normal pBRS (Figure 3-3 A). Upon replacing the culture media with low Mg2+,
the neurons demonstrated continuous, high frequency epileptiform discharges (Figure 3-3
B). The spike frequency observed in cultures treated with low Mg2+ was greater than 3 Hz.
This frequency is consistent with the criteria for clinical SE.

We demonstrated that

treatment with dantrolene (50 µM) failed to slow down the low Mg2+-induced high
frequency spiking (Figure 3-3 C). No change in mean membrane potential or mean input
resistance was observed between groups. There was no significant difference in spike
66

frequency between neurons treated with low Mg2+ plus dantrolene versus low Mg2+
alone—this suggests that dantrolene is unable to inhibit low Mg2+-induced in vitro SE.

Dantrolene maintaines baseline Ca2+ levels 24 and 48 hours post-SE
In order to evaluate whether the dantrolene-mediated changes in [Ca2+]i that were observed
acutely were more long-lasting, we treated neurons with low Mg2+ followed by dantrolene
or vehicle and imaged the cells 24 (Figure 3-4 A) and 48 hrs (Figure 3-4 B) post-treatment.
Neurons treated with low Mg2+ and then vehicle exhibited significantly elevated 340/380
ratios when compared to the control, these numbers were consistent with data collected in
Figure 3-1. Interestingly, in neurons treated with low Mg2+ and then dantrolene, 340/380
ratios were not significantly different from those observed in the control. Thus, 24 hrs
post-SE, dantrolene was able to maintain [Ca2+]i at baseline levels (96.25 ± 5.13% of the
control). Whereas, hippocampal neuronal cultures treated with low Mg2+ and then vehicle
demonstrated significant elevations in [Ca2+]i (120.47 ± 6.95% of the control). n=10 or
more plates with ~100 cells imaged per treatment group at this time point.

At 48 hrs post-treatment, [Ca2+]i in the dantrolene-treated neurons was comparable to
concentrations observed in controls (96.23 ± 3.45% of the control). In contrast, neurons
treated with low Mg2+ and then vehicle, showed significant elevations in 340/380 ratios
compared to both the drug-treated and the control neurons (120.74 ± 3.58% of the control).
n=5 plates with ~60 cells imaged per treatment group at 48 hr time point. Therefore,
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dantrolene appears to be able to maintain [Ca2+]i for at least 48 hrs post-in vitro SE at the
baseline concentrations observed in control neurons.

Dantrolene prevents the development of SREDs 24 and 48 hours post-SE but does not
inhibit SREDs acutely
Also at 24 and 48 hrs post-in vitro SE, neurons were patched using current-clamp
electrophysiology to evaluate for the expression of SREDs. Control neurons demonstrated
“normal” activity consisting of sporadic firing of action potentials (Figure 3-5 A). In
contrast, 84% and 100% of neurons treated with low Mg2+ showed SREDs at 24 and 48 hrs
post-in vitro SE, respectively.

A representative trace is shown that highlights the

characteristics of the observed SREDs (Figure 3-5 B).

These episodes consisted of

paroxysmal depolarization shifts and occurred at a frequency of 5-8 episodes per hour with
each SRED lasting 1-3 minutes.

Neurons from the plates that were treated with low Mg2+

followed by dantrolene showed a marked inhibition in the expression of SREDs 24 hrs
(Figure 3-5 C) and 48 hrs (Figure 3-5 D) post-treatment. Only 10% and 20% showed
SREDs at 24 and 48 hrs post-SE, respectively. Of this small percentage, the SRED
frequency was 1.7/hr at the 24 hr time point and 1.9/hr at the 48 hr time point, a marked
reduction when compared to the SRED frequency observed in cells treated with low Mg2+
but no drug.

To test for potential anti-convulsant properties, we studied whether acutely adding
dantrolene (50µM) to neurons already demonstrating SREDs could inhibit these episodes.
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Dantrolene did not inhibit SREDs when administered acutely (line over Figure 3-5 B
represents treatment with dantrolene); in fact, there was no change in the frequency or
duration of the SREDs. No change in mean resting membrane potential or mean input
resistance was observed between groups.

Dantrolene is neuroprotective
While several studies have demonstrated in other models of epilepsy that dantrolene
exhibits some neuroprotective properties [96-98], we wanted to evaluate whether it could
be neuroprotective when given after the SE-related injury in the hippocampal culture
model.

We treated cells with low Mg2+ for 3 hrs followed by drug or vehicle and

determined cell viability 24 and 48 hrs later (Figure 3-6). Cell viability was ascertained
using PI and Annexin V-FITC. At the 24 hr time point, sham control cultures that had
been subjected to 3 hrs of pBRS instead of low Mg2+ had a fraction cell death of 0.141 ±
0.013. Neurons treated with low Mg2+ and then dantrolene (50 µM) had an average
fraction cell death of 0.138 ± 0.012, consistent with levels observed in the sham control.
Lastly, cultures exposed to 3 hrs of low Mg2+ and then vehicle had an average cell death
fraction of 0.180 ± 0.013, which was significantly higher than the cell death observed in
both drug and control groups. This demonstrated that at 24 hrs post-treatment with low
Mg2+ or pBRS, dantrolene was able to reduce cell death to levels observed in the sham
controls.
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Data was also collected at 48 hrs post-SE. There was no significant difference in fraction
cell death between sham and low Mg2+ plus dantrolene groups; however, low Mg2+ plus
vehicle neurons showed a significant increase from the other two groups. Fraction cell
death was 0.139 ± 0.019, 0.208 ± 0.022, and 0.128 ± 0.028 in sham, low Mg2+ plus
vehicle, and low Mg2+ plus dantrolene treated neurons, respectively. n=7 or more plates
per treatment group and time point. Thus, these results showed that dantrolene-treated
neurons exhibited decreased fraction cell death, which suggests that dantrolene may be
neuroprotective when administered after in vitro SE.

In the rat pilocarpine model of SE-induced AE, dantrolene is able to lower
hippocampal neuronal Ca2+ post-SE
In order to test whether our in vitro observations were valid in a whole animal model, we
utilized the rat pilocarpine model of SE-induced AE. Long-lasting elevations in [Ca2+]i
following SE were first demonstrated in this model [32]. We tested whether dantrolene
was able to lower hippocampal neuronal [Ca2+]i when administered following 1 hr of
pilocarpine-induced SE. Animals were given pilocarpine and allowed to seize for 1 hr,
upon which time they were administered diazepam to terminate the SE and then either
dantrolene (10 mg/kg) or vehicle (DMSO). Then, 24 hrs post-SE, the animals were
sacrificed and hippocampal neurons were acutely isolated and imaged to determine [Ca2+]i.
As demonstrated in Figure 3-7, in the neurons isolated from the naïve control animals, an
average 340/380 ratio of 0.615 ± 0.019 was observed. Neurons from animals in the SE
group had an average 340/380 ratio of 0.763 ± 0.047, which was significantly higher than
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the ratios observed in the naïve control. In contrast, neurons from animals that were in SE
and then treated with dantrolene had an average 340/380 ratio of 0.571 ± 0.014, which was
consistent with that observed in the control but significantly lower than the SE alone
neurons. n=2 or more animals in each group with approximately 30 cells imaged per
animal. This suggests that dantrolene, when administered immediately following SE, may
lower [Ca2+]i in hippocampal neurons in vivo.

Dantrolene does not affect the severity of pilocarpine-induced SE
To ensure that dantrolene was decreasing the [Ca2+]i by directly inhibiting Ca2+ rather than
simply abolishing SE more efficiently and thus, decreasing the severity of the insult, we
quantified the robustness of pilocarpine-induced seizures in animals pre-treated with either
vehicle (DMSO) or dantrolene (10 mg/kg). A modified Racine scale was used that ranged
from 0-6, with no response scored as a 0 and death scored as a 6. Two trained observers
independently scored the SE and scores were averaged for each animal. The severity of
the seizures in pilocarpine plus vehicle scored a 3.5 ± 0.20 and in pilocarpine plus
dantrolene a 3.75 ± 0.25; thus, no significant difference was observed between the two
groups (Figure 3-8).

n=4 animals per group.

The results from this experiment

demonstrated that dantrolene does not affect the severity of seizures induced by
pilocarpine.

The Ca2+ plateau may be maintained in vivo by “leaky” ryanodine receptors

71

It has been demonstrated in a cardiac model of ventricular arrhythmias, phosphorylation of
the RyR leads to increased dissociation of a protein, calstabin [99,100]. Dissociation of
this protein is associated with increased Ca2+ leak from the receptor, leading to ventricular
arrhythmias [99,100]. It can be hypothesized that if RyR are contributing to the Ca2+
plateau post-SE, they are either upregulated or simply more active, allowing for increases
in [Ca2+]i. Western blot analysis was carried out at several time points both during and
after SE. The most interesting change in expression noted was at 1 wk post-SE. At this
time point, no significant difference was observed in quantity of RyR2; however, the
phosphorylated (at serine-2809) form of the receptor was significantly upregulated in the
SE animals when compared to both the naïve and sham controls (Figure 3-9). At 1 hr and
1 day post-SE there does not appear to be an upregulation in either RyR or the
phosphorylated form of this receptor (data not shown). This suggests that ‘leaky’ RyR,
which increase in expression only during the period of epileptogenesis, may contribute to
the ultimate phenotype.

Discussion
This study demonstrated that neuronal injuries such as SE can cause an increase in [Ca2+]i
that is sustained well past the duration of the injury itself in the hippocampal neuronal
culture model of SE-induced AE. Moreover, dantrolene, a RyR inhibitor, is able to both
lower [Ca2+]i to levels observed in control neurons and prevent the development of SREDs
when used after in vitro SE. The observation that an injury-triggered, sustained elevation
in [Ca2+]i (the calcium plateau) exists in vitro correlates closely to findings reported in
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Raza et al [32]. This group demonstrated in the rat pilocarpine model of SE-induced AE
that hippocampal neuronal [Ca2+]i increases during injury and remains elevated only in
those animals that later develop epilepsy [32]. This study suggests that changes in [Ca2+]i
and Ca2+ homeostatic mechanisms lead to a Ca2+ plateau, which may be a
pathophysiological characteristic of neuronal injury and epileptogenesis. Understanding
various cellular and molecular changes that occur either during or following neuronal
injuries is important in developing new therapeutics to prevent the ultimate development of
AE. Therefore, the finding that the changes in [Ca2+]i that were observed in vivo are also
seen in vitro suggests that this culture model may provide a useful tool in screening various
pharmacological agents and performing new molecular modulations in order to prevent
epileptogenesis.

The in vitro model utilizing low Mg2+ to elicit SE-like activity and ultimately, SREDs is a
commonly used model to study various characteristics of both SE and epilepsy such as
pharmacoresistance, plasticity changes, mechanisms of epileptogenesis, and cell death
[18,24,84]. The model exhibits several features consistent with the development of AE in
both animal models and the clinical condition, which make it a useful tool in elucidating
the underlying mechanisms of epileptogenesis and seizures [23,24]. Moreover, the cell
injury observed in the in vitro and in vivo models correspond to that seen in clinical studies
documenting the relationship between SE and neuronal injury [25-27]. It should be noted
that the hippocampal neuronal cultures do not have the true anatomical connections
maintained in slice preparations or the intact brain. However, the cultures are an essential
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tool in the development of new drugs and the study of molecular mechanisms because they
provide a controlled environment to do high-throughput screenings and are more easily
manipulated for molecular studies.

While currently there are several anti-epileptic drugs, there are no anti-epileptogenic drugs.
Such therapeutic agents that can be administered immediately following injury so as to
prevent long-term sequelae, namely the development of AE, would be extremely important
clinically. In this study, we demonstrated that dantrolene, when given post-SE inhibited
the Ca2+ plateau and prevented the development of SREDs in the in vitro low Mg2+ model.
Our results also highlighted that dantrolene did not stop SE or serve as an anti-convulsant
but is neuroprotective in the low Mg2+ model even when used following the neuronal
injury. The ability to offer neuroprotection following a neuronal injury is an important
strategy to prevent the development of injury-related chronic neurological conditions
[101,102]. In this study, many of the in vitro experiments were also replicated in the rat
pilocarpine model and the novel finding that dantrolene was able to lower [Ca2+]i when
administered following SE without diminishing the SE itself was demonstrated. This
finding affirms that the in vitro model may prove to be an effective tool in preliminary
pharmacological studies. Studies have been initiated to determine whether this drug has
anti-epileptogenic properties in vivo, as this would have tremendous clinical implications.

It should be noted that the pharmacological modulation of Ca2+ in vivo is a challenge in
that the ubiquitous nature of this ion suggests that systemic inhibition would potentially
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have numerous side effects [103]. However, a recent clinical trial has utilized a Ca2+chelating agent in patients following stroke and the unpublished results have indicated that
not only are stroke outcome scores improved, but the patients experienced no significant
negative cardiovascular or neurological side effects [88].

The data also suggest that the RyR, a regulator of CICR, may contribute to the
maintenance of the calcium plateau. Much of what is currently known regarding the role
of RyR in epilepsy is based on studies using dantrolene either as a prophylactic
neuroprotective agent before injury so as to prevent the development of AE or as an anticonvulsant after the full development of AE. It has been demonstrated that pre-treatment
with dantrolene blocks the induction phase in hippocampal slice preparation [104].
Another study confirmed these results in the kindling model of epilepsy, showing that
animals pre-treated with dantrolene require significantly greater stimuli to generate
seizures [105]. Moreover, after the animals are kindled, during the chronic phase of
epilepsy, dantrolene has no anti-convulsant effects [91,105]. Thus, while such studies
have suggested that treatment with dantrolene could provide tremendous benefits when
administered before the inciting injury, there is still a need for studies to examine its
effects when administered after the injury, as this would be more clinically relevant. It
remains plausible that during an excitotoxic neuronal injury, the massive release of
glutamate activates NMDAR leading to increased [Ca2+]i. However, following the injury,
CICR mechanisms controlled by the RyR may play a role in maintaining the long-lasting
elevations observed both in the rat pilocarpine model and in the in vitro model used in this
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study. This hypothesis is supported by western blot experiments performed in this study
demonstrating that at 1 week post-SE, during the period of epileptogenesis, there is an
increase in phospho-RyR2 and no change in RyR2 expression in the hippocampus.
Phospho-RyR2 has been associated with increased Ca2+ leak from the RyR, therefore, this
may contribute to the maintenance of a Ca2+ plateau [99,100].

Thus, this study is the first to demonstrate the novel finding that in vitro SE causes longlasting elevations in [Ca2+]i, which can lowered post-injury by treatment with dantrolene in
both in vitro and in vivo models of SE-induced AE. More studies are needed to better
understand and characterize the post-SE Ca2+ plateau, as this may be a useful tool in the
development of anti-epileptogenic targets. Lowering the post-SE Ca2+ plateau may prevent
the second messenger effects that lead to epileptogenesis and the development of chronic
epilepsy.
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Figure 3-1. In vitro SE causes significant, long-lasting elevations in [Ca2+]i
(Ca2+ plateau). Time course comparing sham controls treated with pBRS (solid
black circles) versus neurons treated with low Mg2+ (clear circles) at the end of
in vitro SE (acute) and at various time points following in vitro SE (10 min, 30
min, 60 min, 3 hrs, 6 hrs, 24 hrs). All data represented as average 340/380 ratio
± standard error of the mean (SEM). *p<0.05, n= 6 or more plates with 52-134
neurons imaged per condition at each time point studied.
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Figure 3-2. Dantrolene lowers [Ca2+]i to baseline levels following
in vitro SE. Following 3 hours of in vitro SE (time=0), cells were
treated with either dantrolene (50 µM, clear circles) or vehicle (solid
black circles). 340/380 ratios were recorded every 30 seconds for 20
minutes and normalized to percent of the peak ratio observed at
time=0. *p<0.05, n=6 plates per treatment group with ~60 neurons
imaged per condition.
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Figure 3-3. In vitro SE is not inhibited by dantrolene. A, representative currentclamp trace from control neuron B, neuron in low Mg2+ or in vitro SE and C, neuron
in low Mg2+ plus dantrolene (50 µM).
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Figure 3-4. Dantrolene maintains baseline Ca2+ levels 24 and 48 hrs post-SE.
A, effect of dantrolene (50µM) (light gray bar) versus vehicle (black bar) on
340/380 ratios 24 hrs post-in vitro SE and B, 48 hrs post-in vitro SE. Data
represented as average percent of naïve control ± SEM. *p<0.05, n=10 or more
plates with ~100 cells imaged per treatment group for 24 hr time point; n=5 plates
with ~60 cells imaged per treatment group at 48 hr time point.
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Figure 3-5. Dantrolene prevents the development of SREDs 24 and 48 hours
post-SE but does not inhibit SREDs acutely. A, representative current-clamp trace
from control neuron, B, low Mg2+-treated neuron displaying characteristic SREDs, and
C, neurons treated with low Mg2+ then dantrolene at both 24 hrs and D, 48 hrs posttreatment. Dantrolene did not inhibit SRED activity when added acutely to neurons
displaying SREDs (line over B).
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Figure 3-6. Dantrolene is neuroprotective. A, Cell death was assessed
at 24 hrs and B, 48 hrs post-treatment with pBRS (sham, black bars), low
Mg2+ then vehicle (light gray bars), and low Mg2+ then dantrolene
(50µM) (dark gray bars). No significant difference observed between
sham and drug-treated group at either of the time points. Low Mg2+
neurons demonstrated significantly more cell death than the other two
groups at both 24 and 48 hrs post-treatment. Data represented as mean
fraction cell death ± SEM. *p<0.05, n=7 or more plates per treatment and
time point.
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Figure 3-7. In the rat pilocarpine model of SE-induced AE, dantrolene
is able to lower hippocampal neuronal Ca2+ post-SE. Animals were
treated with vehicle (DMSO) or dantrolene (10 mg/kg) following
pilocarpine-induced SE. 24 hrs later hippocampal neurons were isolated and
imaged for Ca2+ levels. Bar graph compares naïve control animals (black
bar), SE-vehicle animals (light gray bar), and SE-dantrolene animals (dark
gray bar). Data is represented as mean 340/380 ratio ± SEM. *p<0.05, n=2
or more animals in each group with approximately 30 cells imaged per
animal.
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Figure 3-8. Dantrolene does not affect the severity of pilocarpineinduced SE. The severity of pilocarpine-induced seizures was quantified
using a modified Racine scale (0-6, with 0= no response to 6= death) by
averaging scores from 2 independent observers. Data is represented as
mean ± SEM. n=4 animals per group
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Figure 3-9. The Ca2+ plateau may be maintained in vivo by “leaky” RyR2.
A, western blot analysis of hippocampal RyR2 and B, phospho-RyR2 expression
1wk after pilocarpine-induced SE. The data demonstrated no change in the
expression of the 5x102 kD RyR between the naïve, sham, and pilocarpine
groups. However, the expression of the 5x102 kD phospho-RyR is significantly
increased in the pilocarpine-treated group.
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Chapter 4: Levetiracetam Inhibits Both Ryanodine and IP3 Receptor
Activated Calcium Induced Calcium Release in Hippocampal Neurons in
Culture

Introduction
Epilepsy is a major neurological condition that affects approximately 1-2% of the
population worldwide and over 40% of all epilepsy cases arise following a previous brain
insult [106], [107]. Progress has been made in the treatment of epilepsy during the past
decade with the discovery of newer antiepileptic drugs (AEDs) and surgical treatments.
Understanding the mechanisms of action of AEDs has helped in better characterizing
neuronal excitability and may also aid in the development of more effective strategies to
treat epilepsy. Levetiracetam (LEV) is a new AED that is currently in widespread clinical
use. However, LEV appears to have different anticonvulsant properties from other AEDs
[108] and little is known of its mechanism of action except that it acts in a manner and at
sites distinct from other commonly used AEDs [109]. Understanding how this drug works
as an AED and an examination of its ability to block certain cellular changes could provide
insights into its powerful anticonvulsant effect and into the development of more effective
AEDs that act in a similar manner.
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LEV, the S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide, is used to treat a variety
of forms of epilepsy [110]. Unlike many AEDs, LEV does not appear to exhibit direct
effects on GABAergic neurotransmission, fails to interact with the benzodiazepine binding
site, and lacks a significant affinity for GABAergic or glutamatergic receptors
[111],[112],[113]. In addition, compared to other AEDs, LEV is not effective in a use
dependent fashion on sodium channel inhibition, maximal electric shock or
pentylenetetrazole tests for anticonvulsant agents [114]. Most recently, it has been
demonstrated that LEV inhibits GABA-A current run-down [115] and that it binds to the
synaptic vesicle protein 2A (SV2A) [109]. While studies have demonstrated that SV2A
modulates exocytosis of neurotransmitter-containing vesicles [116],[117], the specific
mechanistic relationship between LEV and SV2A remains to be elucidated. Thus, LEV
represents a distinct class of AEDs.

Both changes in Ca2+ homeostatic mechanisms and persistent elevations in baseline
intracellular calcium ([Ca2+]i) have been implicated in playing a key role in the induction
and maintenance of post-injury spontaneous recurrent seizures, or acquired epilepsy (AE)
[4].

Studies have demonstrated that inositol 1,4,5-triphosphate (IP3) and ryanodine

receptor (RyR) mediated calcium-induced calcium release (CICR) play key roles in the
changes in [Ca2+]i observed in epileptic conditions [48],[97]. The effect of LEV on Ca2+
remains to be fully elucidated. However, it is known that LEV does not affect T-type
voltage-gated Ca2+ and exhibits only a mild inhibition of high voltage activated Ca2+
channels [118]. LEV has been shown to inhibit caffeine-induced calcium transients in
88

studies in rat pheochromocytoma PC12 cells [51], and bradykinin-induced calcium
transients in hippocampal slices [119]. Since it has been shown that [Ca2+]i regulation in
hippocampal neurons plays an important role in modulating anticonvulsant and
epileptogenic effects and in mediating injury during seizures [32],[120],[121] it is
important to evaluate the effects of LEV on [Ca2+]i in hippocampal neurons by regulating
IP3R or RyR induced CICR.

This study was initiated to evaluate whether LEV was able to inhibit both IP3R- and RyRinduced CICR in primary hippocampal neurons in culture. The results demonstrate that
LEV affects CICR from IP3 and Ry-sensitive stores, employing the use of single-cell Fura2 imaging to record the response to caffeine and bradykinin, two agents that induce
prototypic IP3 and Ry-mediated calcium release respectively [122],[123]. The exploration
of whether LEV modulates CICR could prove a valuable addition to what is currently
understood on the effects of LEV on hippocampal neurons. Moreover, the ability of a drug
to reduce [Ca2+]i may make it an ideal therapeutic candidate in neuroprotection following
injury and the prevention of long-term plasticity changes leading to epilepsy.

Materials and Methods
Reagents
UCB Pharma supplied Levetiracetam.

Caffeine and bradykinin were obtained from

Sigma-Aldrich (St. Louis, MO). All agents were solubilized in physiologic bath-recording
solution.
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Hippocampal neuronal culture preparation
Preparation of primary mixed hippocampal neuronal culture was performed as previously
described [23].

In summary, hippocampal cells were isolated from 2-day post-natal

Sprague-Dawley rats (Harlan, Frederick, MD). Cells (7.5x104) were plated onto a glial
support layer that was previously plated onto poly-L-lysine (0.05 mg/ml) coated Lab-Tex
glass chambers (Nalge-Nunc International, Naperville, IL). Cultures were maintained at
37°C in 5% CO2/95% O2 incubator and fed twice weekly with Neurobasal A medium
(Invitrogen, Carlsbad, CA) with B-27 serum-free supplement (Invitrogen) and 0.5mM Lglutamine. All experiments were performed on neurons maintained for 14-17 days in vitro
to ensure proper development. All procedures adhered strictly to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by Virginia
Commonwealth University’s Institutional Animal Care and Use Committee.

Ca2+ Microfluorometry
Primary hippocampal cultures were loaded with Fura-2 acetoxymethyl ester and then
placed on the 37°C stage of an Olympus IX-70 inverted microscope (Olympus, Center
Valley, PA) coupled to an ultra-high-speed fluorescence imaging system (Perkin-Elmer
Life and Analytical Sciences, Boston, MA) as described previously [94]. Data were
collected using the UltraVIEW Imaging System. Ratio images were acquired every 5 s
using alternating excitation wavelengths (340/380 nm) with a filter wheel (Sutter
Instruments, Novato, CA) and fura filter cube at 510/540 nm emissions with a dichroic
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mirror at 400 nm [94]. Image pairs were captured for 50 s before and 100 s post-addition
of bradykinin or caffeine, and were corrected for background fluorescence by imaging a
non-indicator loaded field [94].

Data Analysis
Data were statistically analyzed using StatView (Version 5.0.1).

Experiments were

repeated at least three times from different culture batches. The significance of the data
was tested by one-way analysis of variance (ANOVA), or one-way repeated measures
(RM) ANOVA followed by Fisher’s post-hoc test when appropriate.

P < 0.05 was

considered significant for all data analysis.

Results
LEV does not affect baseline [Ca2+]i in cultured hippocampal neurons
To determine the effect of LEV on basal [Ca2+]j, Fura-2 340/380 ratios were measured in
the presence and absence of clinically relevant concentrations [119] of LEV (1, 10, 33, and
100 µM). Cells were pre-treated for 20 minutes with either vehicle (control) or LEV and
Fura-2 ratios were recorded. As shown in Figure 4-1, no significant changes in 340/380
ratios were observed between control and LEV-treated cells during the 20-minute period
following the addition of LEV to the hippocampal culture. These results demonstrate that
at all concentrations tested, LEV does not affect baseline [Ca2+]i.

91

LEV inhibits caffeine induced CICR in hippocampal neurons
Caffeine-induced Ca2+ transients are mediated by stimulation of RyR [119],[124]. Thus, in
order to investigate the effects of LEV on ryanodine induced Ca2+ release, caffeineinduced Ca2+ transients were studied following pre-treatment with 33 µM LEV in
accordance with other studies [119]. Before the addition of caffeine, both control and LEV
pre-treated cells exhibited similar baseline ratios of 0.294±0.018 and 0.319±0.120
respectively, consistent with ratios observed in Figure 4-1. Stimulation with caffeine
elicited a marked increase in [Ca2+]i in control neurons as evidenced by increased 340/380
Fura-2 ratios from the baseline value of 0.294±0.018 to 0.653±0.026, as shown in
representative trace (Figure 4-2 A). Pseudocolor ratio images prior and subsequent to
caffeine stimulation demonstrate this change in calcium following caffeine challenge
(Figure 4-2 B). Thus, the overall change from baseline 340/380 ratio following treatment
with 10mM caffeine was 0.328±0.018 (Figure 4-2 C).

In contrast, cells pre-treated with LEV displayed a significantly diminished response to
caffeine-induced stimulation.

In LEV-treated cells, the baseline 340/380 ratio of

0.319±0.120 increased to a maximum value of 0.445±0.045 following the caffeine
challenge (Figure 4-2 A). Pseudocolor ratio images demonstrate the contrast in the ability
of caffeine to mediate changes in calcium in LEV pre-treated cells when compared to
control (Figure 4-2 B). Thus, as shown in Figure 4-2 C, following treatment with 10mM
caffeine, the overall change from baseline 340/380 ratio was 0.126±0.022 in cells pre-
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treated with 33µM LEV. Therefore, LEV pre-treatment inhibits the height of caffeineinduced Ca2+ transients by 61.50%.

LEV inhibits bradykinin induced Ca2+ transients in hippocampal neurons
To investigate how LEV affects IP3R activated Ca2+ release, the effect of LEV (100µM)
pre-treatment on the inhibition of bradykinin-induced Ca2+ release was evaluated.
Bradykinin-induced Ca2+ transients are mediated by activation of IP3R [125]. Before the
addition of bradykinin, similar baseline ratio values of 0.304±0.020 in control and
0.263±0.015 in LEV (100µM) pre-treated cells were observed, as shown in Figure 4-1.
Control neurons demonstrated a marked increase in [Ca2+]i

when stimulated with

bradykinin (1µM) from baseline to 0.574±0.055 (Figure 4-3 A). This change in Fura-2
ratio in control neurons is shown in the pseudocolor ratio image (Figure 4-3 B). Thus,
treatment with 1 µM bradykinin caused a change in 340/380 ratio of 0.269±0.063 from the
baseline.

LEV-treated neurons showed a markedly diminished response to bradykinin when
compared to control neurons. Stimulation with bradykinin caused a small increase from
baseline to 0.332±0.037 (Figure 4-3 A), as shown also in the pseudocolor ratio image
(Figure 4-3 B). Therefore, neurons pre-treated with 100 µM LEV, bradykinin elicited a
change from baseline of only 0.069±0.032 (Figure 4-3 C). Thus, LEV pre-treatment
inhibited the height of bradykinin-induced Ca2+ transients by 74.35%.
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We found at

concentrations lower than 100µM LEV, there was no significant inhibition in bradykinininduced Ca2+ transients.

Discussion
The results from this study provide direct evidence that LEV inhibits RyR and IP3R
induced CICR in hippocampal neurons in culture. LEV was effective in decreasing both
caffeine-mediated activation of RyR induced CICR and bradykinin activation of IP3R
stimulated CICR. These results indicate that LEV is an effective inhibitor of [Ca2+]i
release mediated by two of the major CICR receptor activated systems. While the effect of
LEV on Ca2+ dynamics in an in vitro model of acquired epilepsy remains to be determined,
Ca2+ is a major second messenger and has been implicated in neurotoxicity, neuronal
plasticity and the maintenance of epilepsy [34], [32]; thus, the ability of LEV to inhibit
CICR may prove to be an important property of this drug.

The experiments performed in this study were designed to test whether LEV was able to
inhibit CICR and to evaluate the mechanisms mediating its effects on these systems, as
dysregulation of RyR and IP3R has been associated with neurotoxicity, neuronal plasticity
and epilepsy [34]. To study the ryanodine system, caffeine was employed because it has
been demonstrated that it functions similarly on RyR as nanomolar concentrations of
ryanodine with the added benefit of faster kinetics and the ability to quickly reverse its
effects by washing [124]. Non-physiologic concentrations of caffeine (in the millimolar
range) are utilized in studies evaluating RyR-mediated Ca2+ release and the Ca2+ response
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elicited has been well-characterized [126],[127],[119].

At sub-millimolar doses, the

actions of caffeine are dependent on cytosolic concentrations of Ca2+, whereas, at
concentrations greater than 5 mM, caffeine causes a Ca2+ independent activation of the
ryanodine receptor [128]. Thus, using caffeine is an established method to activate RyRmediated Ca2+ release [126],[127],[119]. One study employed caffeine in a hippocampal
slice model to suggest that LEV reduces caffeine-mediated Ca2+ transients [119]. In
studying IP3R-mediated CICR, lack of commercially available membrane-permeable IP3
makes bradykinin an ideal choice to study this system because it has been demonstrated
that it stimulates Ca2+ release through IP3 stores [125]. One study in PC12 cells
demonstrated that LEV was able to reduce bradykinin-induced Ca2+ transients [51].
However, no studies have investigated the effect of LEV on both IP3 and RyR in the
highly relevant hippocampal culture model. Conducting these studies in hippocampal
cultures is of utility because networks of hippocampal neurons have been used as models
to study AE [23],[4].

Our results supplement the current literature aimed at elucidating the mechanism of action
of LEV [115],[118],[129]. Currently, little is known regarding the mechanism behind the
anti-epileptic properties of LEV. Studies have demonstrated that while LEV does not
exhibit any direct action on GABAergic transmission and does not show affinity for
GABAergic or glutamatergic receptors, it does induce a change in GABA turnover in the
striatum [111],[112],[113],[108]. Other studies have focused on biochemical alterations
induced by LEV and have found that it decreases levels of the amino acid taurine, a low
95

affinity agonist for GABAA receptors, in the hippocampus but does not elicit changes in
other amino acids [129].

The most promising mechanistic hypothesis explaining the actions of LEV has come from
experiments that suggest that the action of LEV is presynaptic, as it binds to the
presynaptic membrane protein, SV2A [130],[109]. SV2A is ubiquitously expressed in the
brain [131], yet little is known regarding the effects of the interaction between SV2A and
LEV. It appears that SV2A is involved in controlling exocytosis of neurotransmittercontaining vesicles [116],[132].

More recently, it has been demonstrated that LEV

prevents GABA-A current run-down [115]; thus, increasing inhibitory tone. Interestingly,
it has been observed that increases in cytoplasmic Ca2+ triggered by caffeine-induced Ca2+
release from intracellular pools depress the GABA-A response [133]. In light of our
studies, it will be interesting to study whether the ability of LEV to inhibit RyR-mediated
CICR contributes to the inhibition of GABA-A current run-down following treatment with
LEV.

Studying the effect of LEV on CICR mechanisms is also important, since alterations in
[Ca2+]i have been associated with many of the second messenger effects of Ca2+ [134] and
have been shown to play an important role in underlying neurotoxicity, neuronal plasticity,
and the development of AE [34], [32]. Moreover, the neuroprotective properties of LEV
have been observed in several different models [135],[136],[137]. Following neuronal
injury, excitotoxic glutamate release has been associated with increased stimulation of
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NMDA receptors and the massive influx of Ca2+ into the cell [138],[4],[139]. This influx
of Ca2+ triggers CICR and this irreversible Ca2+ overload has been linked to cell death
[140],[97],[134]. Agents that can reduce these elevations in [Ca2+]i have the potential to be
neuroprotective [34] and thus, the findings in this study may shed light on a new
application for LEV.

This study demonstrates that LEV is able to significantly inhibit Ca2+ release through both
the RyR and IP3R systems. The ability of LEV to modulate the two major CICR systems
demonstrates an important molecular effect of this agent on a major second messenger
system in neurons. Further studies on the effects of LEV may offer insight into novel
therapeutic uses for this agent and may offer further opportunities to study Ca2+-mediated
epileptogenesis, neuronal plasticity and neurotoxicity.
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Figure 4-1. LEV has no effect on baseline [Ca2+]i in cultured
hippocampal neurons. Hippocampal neurons loaded with Ca2+ indicator,
Fura-2, were treated for 20 minutes with vehicle (control) or LEV (1, 10,
33, and 100 µM). No significant difference in 340/380 ratio was observed
between vehicle and drug treated cells at all concentrations tested. n=9, 3,
3, 7, 5 (Vehicle, 1, 10, 33, 100 µM LEV, respectively) plates with ~15-20
cells imaged per plate.
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Figure 4-2. LEV inhibits caffeine induced CICR in cultured
hippocampal neurons. A, representative time course of Ca2+ 340/380
ratios with baseline normalized to zero before and after 10 mM caffeine
challenge in control (n=74) and LEV pre-treated (n=88) cells. 5 s intervals
showing ratios 25 s before and 55 s following the addition of caffeine are
displayed. Caffeine elicits an increase in basal Ca2+, this increase is
diminished in cells pre-treated with LEV (33 µM). B, 340/380 ratio
images of representative cell before and after caffeine in both control and
LEV-treated group. C, LEV inhibits height of caffeine-induced Ca2+
transients by 61.50%. An increase of 0.328±0.0183 from the baseline was
observed in control neurons post-caffeine; whereas, upon caffeine
stimulation cells pre-treated with LEV showed a change from baseline of
0.126±0.0229. n=5, control and n=6, LEV group, with ~15 cells imaged
per plate (p=0.0002).
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Figure 4-3. LEV inhibits bradykinin induced Ca2+ transients in
hippocampal neuronal cultures. A, representative time course of Ca2+
340/380 ratios with baseline normalized to zero before and after 1µM
bradykinin challenge in control (n=119) and LEV-treated (n=82) cells. 5 s
intervals showing ratios 20 s before and 50 s following the addition of
bradykinin are displayed. Bradykinin elicits an increase in basal Ca2+, this
increase is diminished in cells pre-treated with LEV (100 µM). B, 340/380
ratio images of representative cell before and after bradykinin in both control
and LEV-treated group. C, LEV inhibits height of bradykinin-induced Ca2+
transients by 74.35%. An increase of 0.269±0.063 from the baseline was
observed in control neurons post-bradykinin; whereas, upon bradykinin
stimulation cells pre-treated with LEV showed a change from baseline of
0.069±0.032. n=7 (control), n=5 (LEV group) with ~15 cells imaged per
plate (p<0.05).
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Chapter 5: The Novel Antiepileptic Drug Carisbamate (RWJ 333369) Is
Effective in Inhibiting Spontaneous Recurrent Seizure Discharges and
Blocking Sustained Repetitive Firing in Cultured Hippocampal Neuron

Introduction
Epilepsy is one of the most common neurological disorders affecting approximately 1-2%
of population worldwide [141,142]. It is characterized by the occurrence of spontaneous,
recurrent unprovoked seizure discharges [143]. A seizure is the symptomatic, behavioral
manifestation of abnormal, disordered, spontaneous, and synchronized high frequency
firing of populations of neurons in the CNS [4,142,143]. Epilepsy also has severe socioeconomic implications [144]. Although great advances have been made in the development
of newer antiepileptic drugs (AEDs) and surgical interventions for the treatment of
epilepsy, approximately 40% of the patients are still refractory to treatment with
conventional AED’s [141,145]. A sizeable population of epileptic patients deals with the
issue of daily management of epilepsy that ultimately affects their quality of life [146].
Thus, there is a growing demand for developing newer medications to treat epilepsy.
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Carisbamate, or RWJ-333369 (S-2-O-carbamoyl-1-o-chlorophenyl-ethanol), is a novel
neuromodulator

initially

developed

by

SK-Biopharmaceuticals and

now under

development by Johnson & Johnson, Pharmaceutical Research & Development L.L.C. It
has completed phase 2 clinical trials for the treatment of epilepsy [147]. Carisbamate is a
monocarbamate derivate of the broad spectrum AED felbamate, that is no longer used
clinically due to its hematological and hepatic toxicities [148]. Unlike felbamate,
carisbamate has only two carbons in its side chain and only one carbamate group that
prevents the formation of the toxic aldehyde causing the toxicity of felbamate [147].
Because of its potential safety, carisbamate has been evaluated as a novel AED and has
been demonstrated to possess anticonvulsant activity in a variety of in vivo seizure models
including hippocampal and corneal kindling [147,149] and the GAERS model of absence
epilepsy [150]. It also inhibits spontaneous recurrent seizures after kainite [151] or LiPilocarpine [152] induced epilepsy. Carisbamate is also anticonvulsant against bicuculline
and picrotoxin induced seizures and in pentylenetetrazole and maximal electroshock
induced seizure models [147,149,153]. However, the exact mechanism of action of
carisbamate is still unknown. The dicarbamate, felbamate, has been reported to affect a
variety of ionic currents including the sodium (Na+) [154], calcium (Ca2+) [155], and Nmethyl d-aspartate (NMDA) currents [156]. However, significance of this action for
seizure protection is uncertain. Thus, it is important to determine mechanisms underlying
the antiepileptic effects of carisbamate.
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This study was initiated to investigate mechanisms underlying the antiepileptic effects of
carisbamate using the hippocampal neuronal culture model of status epilepticus (SE)induced acquired epilepsy (AE) [4,23,157]. The low Mg2+ model of AE utilizes an episode
of continuous seizure activity (in vitro SE) for 3 hrs to induce epileptogenesis. Upon return
to solutions containing MgCl2, networks of neurons manifest synchronized spontaneous
recurrent epileptiform discharges (SREDs) for the life of the neurons in culture (in vitro
AE). The low Mg2+ model of SREDs in hippocampal neuronal cultures has been routinely
used to characterize biochemical, electrophysiological, and molecular mechanisms
underlying epilepsy in an in vitro setting [4,48,157,158]. This in vitro model allows for
careful control of the neuronal environment and is thus, ideally suited to evaluate the
effects of various investigational compounds on electrographic seizure activity.

Materials and Methods
Reagents
All reagents were purchased from Sigma Chemical Co (St. Louis, MO) unless otherwise
noted. Sodium pyruvate, minimum essential media containing Earle’s salts, fetal bovine
serum and horse serum were obtained from Gibco-BRL (Invitrogen Corp., Carlsbad, CA).
Carisbamate was provided by Johnson & Johnson, Pharmaceutical Research &
Development L.L.C., Titusville, NJ, USA and was dissolved in sterile water made slightly
basic with sodium hydroxide and diluted to a final concentration in buffer.
Hippocampal neuronal culture preparation
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All animal use procedures were in strict accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and approved by Virginia
Commonwealth University’s Institutional Animal Care and Use Committee. Studies were
conducted on primary mixed hippocampal neuronal cultures prepared as described
previously with slight modifications [23,159,160]. In brief, hippocampal cells were
obtained from 2-day postnatal Sprague-Dawley rats (Harlan, Frederick, MD) and plated at
a density of 1 x 105 cells/cm2 onto 35-mm Falcon cell culture dishes (Becton Dickinson and
Co., Franklin Lakes, NJ) previously coated with poly-L-lysine (0.05 mg/ml). Glial cultures
were maintained at 37°C in a 5% CO2/95% air atmosphere and fed thrice weekly with glial
feed (minimal essential media with Earle’s Salts, 25 mM HEPES, 2 mM L-Glutamine, 3
mM Glucose, and 10% fetal bovine serum). When confluent, glial beds were treated with 5
µM cytosine arabinoside for 2 days to curtail cell division. On the 13th day in vitro, the
media was fully replaced with a 5% horse serum supplemented neuronal feed (composition
given below) in preparation for neuronal plating on the following day. At this time, these
cultures predominantly consisted of glial cells with few, if any, neurons. On the 14th day in
vitro, hippocampal cell suspension was plated on these confluent glial beds at a density of
2 x 105 cells/cm2.

24 hrs after plating, cultures were treated with 5 µM cytosine

arabinoside to inhibit non-neuronal growth. Cultures were maintained at 37°C in a 5%
CO2/95% air atmosphere and fed twice weekly with neuronal feed (minimal essential media
with Earle’s Salts, 25 mM HEPES, 2 mM L-Glutamine, 3 mM Glucose, 100 µg/ml
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transferrin, 5 µg/ml insulin, 100 µM putrescine, 3 nM sodium selenite, 200 nM
progesterone, 1 mM sodium pyruvate, 0.1% ovalbumin, 0.2 ng/ml triiodothyroxine and 0.4
ng/ml corticosterone supplemented with 20% conditioned media). These mixed cultures
were used for experiments from 13 days in vitro following neuronal plating through the life
of the cultures.
Whole-cell current clamp recordings
Whole-cell current clamp recordings were performed using previously established
procedures [23,159,160]. Briefly, a cell culture dish was mounted on the stage of an
inverted microscope (Nikon Diaphot, Tokyo, Japan) continuously perfused with
physiological basal recording solution (pBRS) containing (in mM): 145 NaCl, 2.5 KCl, 10
HEPES, 2 CaCl2, 1 MgCl2, 10 glucose, and 0.002 glycine, pH 7.3, and osmolarity adjusted
to 325 ± 5 mOsm with sucrose. Patch electrodes with a resistance of 2 to 4 mΩ were pulled
on a Brown-Flaming P-80C electrode puller (Sutter Instruments, Novato, CA), firepolished and filled with a solution containing (in mM): 140 K+ gluconate, 1.1 EGTA, 1
MgCl2, and 10 Na-HEPES, pH 7.2, osmolarity adjusted to 290 ± 10 mOsm with sucrose.
Whole-cell recordings were carried out using an Axopatch 200B amplifier (Molecular
Devices, Foster City, CA) in a current-clamp mode. Data were digitized via Digidata
1322A (Molecular Devices, Foster City, CA) and transferred to VHS tape using a PCM
device (Neurocorder, New York, NY) and then played back on a DC-500 Hz chart recorder
(Astro-Med Dash II, Warwick, RI). Carisbamate was included in the recording solution
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and applied to the whole-cell dish by using a multi-channel gravity-feed perfusion system
(Warner Instruments, Hamden, CT).
Hippocampal neuronal culture model of SREDs
SREDs were induced into neuronal cultures by exposing them for 3 hrs to a solution
containing no added MgCl2 (low Mg2+) using procedures described previously
[23,159,160]. Briefly, after the removal of maintenance media, neurons were gently
washed with pBRS or low Mg2+ and then allowed to incubate in this solution at 37oC under
5% CO2/95% air atmosphere. At the end of the 3-h period, cultures were restored to the
physiological concentration (1 mM) of MgCl2, returned to maintenance media, and
incubated at 37oC under 5% CO2/95% air atmosphere.
Sustained repetitive firing in cultured hippocampal neurons
Sustained repetitive firing (SRF) was induced by S-90 Tri-level Stimulator (Medical
Systems Corp., Greenvale, NY) by depolarizing pulses of 500 ms duration, 0.3 Hz and
increasing current strength from 0.1 to 0.5 nA through the micropipette. The duration and
frequency of depolarizing pulses were kept constant for all experiments. Current strength
was increased until the cell under study exhibited a suitable number of action potentials
throughout the duration of the depolarizing pulse.
Hippocampal neuronal culture model of SE
After 2 weeks in cultures, neurons were utilized for experimentation. SE-like activity was
induced in vitro as described previously [23]. Maintenance media was replaced with pBRS
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with or without MgCl2. Continuous high frequency epileptiform bursts (in vitro SE) were
induced by exposing neuronal cultures to pBRS without added MgCl2 (low Mg2+). The
high frequency spiking continued until pBRS containing 1 mM MgCl2 was added back to
the cultures. Unless indicated as low Mg2+ treatment, experimental protocols utilized pBRS
containing 1 mM MgCl2.
Data analyses
Data are reported as mean ± SEM. For concentration-response analysis, suppression of SE
or SREDs was determined as a percentage decrease in frequency over increasing
concentrations of carisbamate. Status epilepticus frequency was determined by counting
individual epileptiform bursts over a recording duration of 5 min for each neuron analyzed
before and after application of the drug. SRED frequency was determined by counting
individual SREDs over a recording duration of 30 min for each neuron analyzed before and
after application of the drug. Frequency analysis was carried out on multiple neurons at
each concentration of carisbamate. SRF data were examined using one-way analysis of
variance (ANOVA) followed by a post-hoc Tukey test. Data were analyzed using
SigmaStat 2.0 and graphs were generated using SigmaPlot analysis software 8.02 (SPSS
Inc., Chicago, IL).
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Results
Effects of carisbamate on SREDs
Whole-cell current clamp recordings from neurons in cultures 1 day after a 3 hr low-Mg2+
treatment demonstrated SREDs or in vitro seizure events. Figure 5-1 B shows recording
from a neuron that exhibited 3 SREDs that lasted between 1-2 min in duration. These
SREDs occurred for the life of the neurons in culture and manifested paroxysmal
depolarization shifts, pathophysiological characteristic of AE. SREDs started in an
unprovoked manner and stopped spontaneously. Multiple recordings from adjacent
neurons demonstrate that these SREDs were synchronous events occurring throughout the
neuronal network in populations of neurons (data not shown, [23]). Thus, SREDs are the
in vitro equivalent of spontaneous electographic seizure discharges. Age-matched control
neurons revealed "normal" baseline activity consisting of intermittent action potentials
(Figure 5-1 A). There were no significant differences in membrane potential and input
resistance between control and epileptic neurons.

To evaluate the antiepileptic effects of carisbamate we used the in vitro hippocampal
neuronal culture model of SREDs. As shown in Figure 5-1 C, application of carisbamate
(100 µM) fully inhibited the expression and reoccurrence of SREDs. The effects of
carisbamate were dose dependent and concentrations of 10-100 µM caused a progressive
decrease in the occurrence of SREDs. The graph in Figure 5-2 demonstrates the effects of
increasing carisbamate concentration on the frequency of SREDs. Carisbamate displayed a
steep dose-response curve. The lower doses were less effective in stopping SREDs while
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higher doses produced almost complete inhibition of SREDs. The ED50 value was
computed to be 58.75 ± 2.43 µM. Carisbamate was applied to neurons during SREDs and
it took approximately 10-15 min for its antiepileptic effect to be fully manifested. Upon
washout of carisbamate, SREDs returned and seizures recurred after approximately 15-20
min (Figure 5-1 C).

Carisbamate produced identical effects to well-known anticonvulsants in this in vitro
model of AE (Sombati and DeLorenzo, 1995). Phenytoin, a clinically used AED, is a usedependent Na+ channel blocker that is utilized for the treatment of generalized tonic-clonic
and partial complex seizures [161,162]. As shown in Figure 5-1 D, Phenytoin (10 µM) at
therapeutically relevant concentrations reversibly blocked SREDs. Phenobarbital, a
GABAergic agonist, is another anticonvulsant that effectively blocked SREDs in our
model (data not shown). Ethosuximide, a T-type Ca2+ channel blocker used to treat
absence seizures, failed to block SREDs at concentrations up to 1 mM in this model
(Figure 5-1 E). These results are consistent with clinical effects of these drugs for the
treatment of temporal lobe epilepsy.
Effect of carisbamate on SRF
Several AEDs including phenytoin, carbamazepine, phenobarbital, and lamotrigine are
known to block SRF in neurons [161,162]. This effect of AEDs is believed to be due to
their ability to block voltage-gated Na+ channels. We investigated if carisbamate shares
this property with other AEDs. Cultured hippocampal neurons respond to a sustained
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depolarizing current by generating a series of action potentials. Under control conditions, a
depolarizing current (0.5 nA, 0.3 Hz) elicited between 4-10 action potentials (spikes)
(Figure 5-3 A). Carisbamate (100 µM) caused a significant (p < 0.001) decrease in the
frequency of spikes elicited by the depolarizing current and abolished the late sustained
phase of firing without blocking the initial spike (Figure 5-3 B,D). These results suggest
that carisbamate blocks Na+ channels in a state- or use-dependent manner. While the
effects of carisbamate were reversible, it took between 10-15 min for the restoration of
SRF following washout (Figure 5-3 C). Spike frequency following carisbamate washout
was not significantly different from pre-carisbamate spike frequency (Figure 5-3 D).

Effects of carisbamate on low Mg2+ induced high frequency spiking
In normal conditioned media, cultured hippocampal neurons exhibited spontaneous action
potentials that were comparatively infrequent and irregular (Figure 5-4 A). However, upon
removal of Mg2+ from extracellular environment, neurons generated bursts of action
potentials resulting in the development of continuous high frequency epileptiform
discharges (Figure 5-4 B). This epileptiform activity consisted of repetitive burst
discharges with each burst comprised of multiple spikes overlaying a depolarization shift.
Spike frequency upon removal of Mg2+ was greater than 3 Hz, meeting the criteria of
clinical electrographic in vitro SE [23]. This technique has been widely used to model the
electrographic SE-like condition in vitro.
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As shown in Figure 5-4, clinically used AEDs including phenytoin (50 µM) and
ethosuximide (1 mM) at therapeutic concentrations or higher failed to stop low Mg2+
induced in vitro SE activity in this model [23]. This type of in vitro continuous seizure
discharge has been extremely refractory to anticonvulsant treatment [23,159,160]. We
investigated if carisbamate could act differently and block this high frequency spike
activity. Treatment with carisbamate (100 µM) appeared to marginally slow down the low
Mg2+-induced high frequency spiking (Figure 5-4 E). However, this effect was not
significantly different from low Mg2+ treated neurons alone. The graph in Figure 5-5 shows
the effects of increasing concentrations of carisbamate on the inhibition of low Mg2+induced high frequency spike activity. Even at concentrations of up to 200 µM,
carisbamate inhibited spike frequency only by 10-15%. The ED50 value for effects of
carisbamate on inhibition of SE-like activity could not be calculated since the effects never
reached 50% inhibition. High frequency firing was restored within 10-15 min following
washout of carisbamate with low Mg2+ solution.
Discussion
This study demonstrates that carisbamate blocks the expression of SREDs in the
hippocampal neuronal culture model of in vitro AE. In addition, carisbamate reduced the
frequency of action potentials generated during depolarization-induced SRF. Our results
are consistent with other studies that have demonstrated antiepileptic properties of
carisbamate in various in vivo models of seizures [147,149-153].

While the exact

mechanism of action of carisbamate is actively pursued, the ability of carisbamate to
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inhibit depolarization-induced SRF suggests that it may block Na+ channels in a state- or
use-dependent manner and that this effect may account in part for some of the
anticonvulsant effects of carisbamate.

The majority of patients with epilepsy have their seizures well controlled with
conventional AEDs; however, approximately 40% of patients manifest refractory epilepsy
[163,164]. Thus, there is a significant need to develop new AEDs to attempt to treat
refractory patients. Novel AEDs are being designed to treat drug resistant epilepsy
[147,149]. In fact, out of the currently available 20 AEDs, 8 were introduced in past
decade [165]. However, despite the introduction of newer AEDs, the prognosis still
remains poor [163,166]. Thus, there are continual efforts to develop more efficacious drugs
that have fewer side effects and a wider margin of safety [147,149].

The novel neuromodulator, carisbamate, displays high potency in a variety of in vivo and
in vitro seizure models at doses well below those that produce CNS toxicity [167].
However, its mechanism of action remains to be elucidated. Chemically, carisbamate is a
monocarbamate that is a derivative of the dicarbamate, felbamate. Felbamate has been
shown to affect Na+, Ca2+, and NMDA currents [154] [155,156]. All of these effects could
contribute to the antiepileptic properties of dicarbamates. While the effects of carisbamate
on various ionic currents and the contribution of these effects towards its antiepileptic
profile remain to be investigated, our studies indicate that a use- or state-dependent block
of Na+ channels could account for such properties. Alterations in intracellular Ca2+
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dynamics have been shown to affect the expression of SREDs in this in vitro model of
acquired epilepsy. The ability of carisbamate to inhibit SREDs could also be due to its
ability to restore altered Ca2+ homeostasic mechanisms in epileptic neurons. It will be
interesting to investigate this possibility in future studies

The model of recurrent epileptiform discharges after low Mg2+-induced in vitro SE is a
commonly used system to study the mechanisms underlying seizures, seizure-induced
plasticity, and the development of pharmacoresistant seizures [4,168-170]. The
hippocampal neuronal culture model of SREDs mimics the electrophysiological and
molecular changes observed during the induction, maintenance, and expression phases of
epilepsy [4]. Moreover the SREDs exhibited in cultured neurons manifest identical
electrographic properties, neuronal population synchronicity, and anticonvulsant sensitivity
as observed in epileptic seizures recorded in in vivo models [4,23,83]. While the neuronal
cultures do not have true anatomical connections and do not display clinical seizures, the
hippocampal neuronal culture models offer the ability to utilize various in vitro techniques
to study molecular mechanisms underlying epilepsy and mechanisms of actions of
investigational drugs in a more controlled environment.
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Figure 5-1. Effects of carisbamate on SREDs in cultured hippocampal
neurons. A, Current-clamp recording from a representative control neuron
displaying baseline activity consisting of intermittent action potentials. B,
Recording from an “epileptic” neuron 1-day following a 3-h exposure to low Mg2+
solution demonstrates occurrence of characteristic SREDs. Three SREDs or
spontaneous seizure episodes lasting ~60-90s can be seen in this recording frame.
These SREDs occurred throughout the life of the cultures and are indicative of the
pathophysiological “epileptic” phenotype. Effects of various AEDs on SREDs in
cultured hippocampal neurons. Application of C, carisbamate (100 µM) or D,
phenytoin (10 µM) to the epileptic neurons abolished the expression of SRED
activity. However application of E, ethosuximide (1 mM) failed to stop SRED
activity. The effects of AEDs on SREDs were reversible and seizures reappeared
following drug washout.
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Figure 5-2. Carisbamate inhibits low Mg2+-induced SRED activity
in a concentration dependent manner. Frequency of SREDs in the
presence of varying concentrations of carisbamate was measured over a
30-min period and then plotted as a percentage change (inhibition)
from control (absence of carisbamate) SRED frequencies. Carisbamate
blocked low Mg2+-induced SREDs with an EC50 = 58.75 ± 2.43 µM.
Each data point represents percentage change from control ± S.E.M. (n
= 5-7 neurons/ concentration).
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Figure 5-3. Carisbamate inhibition of sustained repetitive firing (SRF)
in cultured hippocampal neurons. Depolarizing pulses (0.5 nA, 1 s) were
applied during each set of recordings obtained as follows: A, control period
before application of carisbamate, B, during the application of carisbamate
(100 µM) and C, following carisbamate washout. D, A bar graph
representation of average inhibitory effect of carisbamate on SRF in
hippocampal neurons. Data represented as mean spike frequency ± S.E.M. (n
= 6, * p < 0.001).
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Figure 5-4. Effect of carisbamate and other AEDs on low Mg2+induced SE in cultured hippocampal neurons. A, Representative
control neuron displaying intrinsic baseline activity consisting of
spontaneous action potentials. B, Induction of continuous epileptiform
status epilepticus activity in a neuron upon low Mg2+ treatment. Effects
of clinically used AEDs on low Mg2+ induced high frequency spiking. C,
phenytoin (50 µM) or D, ethosuximide (1 mM) failed to block high
frequency spiking. E, carisbamate (100 µM) appeared to slow down
spike frequency compared to phenytoin or ethosuximide but this effect
was not different from neurons exposed to low Mg2+ alone.
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Figure 5-5. Concentration-response analysis of effects of
carisbamate on low Mg2+ induced high frequency spiking in
cultured hippocampal neurons. Increasing concentrations of
carisbamate had little effect on low Mg2+ induced high frequency
spiking. Even at concentrations of up to 200 µM only a 10-12%
inhibition was achieved. Spike frequencies in the presence of
varying concentrations of carisbamate were measured over a 15min period and then plotted as a percentage change (inhibition)
from control (absence of carisbamate) spike frequencies. An EC50
value could not computed since 50% inhibition was not achieved.
Each data point represents percentage change from control ±
S.E.M. (n = 5-7 neurons/ concentration).
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Chapter 6: Carisbamate Prevents the Development and Expression of
Spontaneous Recurrent Epileptiform Discharges and is Neuroprotective
in Cultured Hippocampal Neurons

Introduction
Epilepsy is a common neurological disorder affecting approximately 1–2% of the
population worldwide and is characterized by the occurrence of recurrent, unprovoked
seizures[81,171]. It is estimated that 50% of epilepsy cases are of idiopathic (genetic)
etiology, but the other 50% develop after a presumed brain injury, such as status
epilepticus (SE), stroke, traumatic brain injury, or CNS infections, and are classified as
acquired epilepsy (AE), resulting in permanent plasticity changes in the brain that cause
the development of spontaneous recurrent seizures [4,81]. This process of transformation
of healthy CNS tissue with a functional balance between excitation and inhibition to a
brain manifesting hyperexcitable neuronal epileptiform discharges is called epileptogenesis
[4,18,172]. Despite important advances in our understanding of the regulation of neuronal
excitability and antiepileptic drug (AED) action [173,174], approximately 40% of patients
remain refractory to treatment with conventional AEDs [81,175]. Thus, it is important to
develop novel AEDs [176]. Compounds that prevent the process of epileptogenesis have
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important clinical ramifications, because administering such agents following a brain
injury could potentially prevent acquired epilepsy [4,172,177].

Carisbamate (RWJ 333369) is a novel AED with a wide margin of safety in humans based
on a completed phase 2 clinical trial for the treatment of epilepsy [178,179]. Carisbamate
has been reported to possess anticonvulsant effects in a variety of seizure models [180].
Although there are no peer-reviewed studies demonstrating that carisbamate can prevent
epileptogenesis, a recent abstract presented at the American Epilepsy Society's annual
meeting did show that carisbamate might delay or prevent the occurrence of spontaneous
seizures in the lithium-pilocarpine model of epilepsy [181]. The mechanism of action of
carisbamate is still unknown and is being investigated by several research groups including
our own. However, there are no studies evaluating the ability of carisbamate to inhibit the
development and expression of epileptiform discharges in vitro and comparing it to other
conventional AEDs.

This study was initiated to investigate the ability of carisbamate to inhibit the development
and expression of spontaneous recurrent epileptiform discharges (SREDs) in cultured
hippocampal neurons injured following SE-like activity in vitro.

While the neuronal

cultures do not have true anatomical connections and do not display clinical seizures, this
in vitro model has been routinely used to characterize biochemical, electrophysiological,
and molecular mechanisms underlying acquired epilepsy [4,24,48,67].

Moreover, the

SREDs demonstrate electrographic properties, neuronal population synchronicity, and
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anticonvulsant sensitivity identical to those of epileptic seizures recorded in vivo [4,23].
This system also allows for control of the extracellular milieu and is ideally suited to
evaluate the effects of investigational compounds on in vitro seizure-like activity.

Materials and Methods
Reagents
All the reagents were purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.) unless
otherwise noted. Carisbamate was provided by Johnson & Johnson (Pharmaceutical
Research & Development L.L.C., Titusville, NJ, U.S.A.). Carisbamate and phenytoin were
dissolved in sterile water made slightly basic with sodium hydroxide. Phenobarbital was
dissolved in sterile water. All stocks were made fresh daily.

Hippocampal neuronal culture preparation
All animal use procedures were in strict accordance with the National Institutes of Health
Guide

for

the

Care

and

Use

of

Laboratory

Animals

and

approved

by

Virginia Commonwealth University's Institutional Animal Care and Use Committee.
Studies were conducted on primary mixed hippocampal neuronal cultures prepared as
described previously with slight modifications [23,24]. In brief, hippocampal cells were
obtained from 2-day postnatal Sprague–Dawley rats (Harlan, Frederick, MD, U.S.A.) and
plated at a density of 2 × 105 cells/cm2 onto glial beds grown on 35-mm Falcon cell culture
dishes (Becton Dickinson and Co., Franklin Lakes, NJ, U.S.A.) previously coated with
poly-L-lysine (0.05 mg/mL). Cultures were maintained at 37°C in a 5% CO2/95% air
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atmosphere and fed twice weekly with neuronal feed (minimal essential media with Earle's
Salts, 25 mM HEPES, 2 mM l-Glutamine, 3 mM Glucose, 100 µg/mL transferrin, 5 µg/mL
insulin, 100 µM putrescine, 3 nM sodium selenite, 200 nM progesterone, 1 mM sodium
pyruvate, 0.1% ovalbumin, 0.2 ng/mL triiodothyroxine, and 0.4 ng/mL corticosterone
supplemented with 20% conditioned media).

These mixed cultures were used for

experiments from 13 days in vitro following neuronal plating through the life of the
cultures.

Whole-cell current clamp recordings
Whole-cell current clamp recordings were performed using previously established
procedures [23,24]. Briefly, a cell culture dish was mounted on the stage of an inverted
microscope (Nikon Diaphot, Tokyo, Japan) continuously perfused with physiological basal
recording solution (pBRS) containing (in mM): 145 NaCl, 2.5 KCl, 10 HEPES, 2 CaCl2,
10 glucose, and 0.002 glycine, pH 7.3, and osmolarity adjusted to 325 ± 5 mOsm with
sucrose. Patch electrodes with a resistance of 2–4 mΩ were pulled on a Brown-Flaming P80C electrode puller (Sutter Instruments, Novato, CA, U.S.A.), fire-polished and filled
with a solution containing (in mM): 140 K+ gluconate, 1.1 EGTA, 1 MgCl2, and 10 NaHEPES, pH 7.2, osmolarity adjusted to 290 ± 10 mOsm with sucrose. Whole-cell
recordings were carried out using an Axopatch 200B amplifier (Molecular Devices, Foster
City, CA, U.S.A.) in a current-clamp mode. Data were digitized via Digidata 1322A
(Molecular Devices) and transferred to VHS tape using a PCM device (Neurocorder, New
York, NY, U.S.A.) and then played back on a DC-500 Hz chart recorder (Astro-Med Dash
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II, Warwick, RI). All the recordings were performed in the current-clamp mode at I = 0
setting. No current was injected at any stage of recording in the presence or absence of
drugs.

Hippocampal neuronal culture model of SREDs
SREDs were induced in neuronal cultures by exposing them for 3 hrs to a solution
containing no added MgCl2 (low Mg2+) using procedures described previously [23,24].
Briefly, after the removal of maintenance media, neurons were gently washed with 3 × 1.5
ml of pBRS (with or without 1 mm MgCl2) and then allowed to incubate in this solution at
37°C under 5% CO2/95% air atmosphere. At the end of the 3 hr period, cultures were
restored to the physiological concentration (1 mm) of MgCl2 by gently washing with
minimum essential medium, returned to the maintenance medium, and incubated at 37°C
under 5% CO2/95% air atmosphere. Thus, low Mg2+ treatment was carried out with pBRS
without added MgCl2, whereas sham controls were treated with pBRS containing 1 mm
MgCl2.

Analysis of the effects of carisbamate on the in vitro development and expression of
epileptiform discharges
To investigate the effects of carisbamate on the generation and expression of SREDs,
neuronal cultures were first subjected to 3 hrs of low Mg2+-induced continuous highfrequency epileptiform activity to mimic in vivo SE. At the end of the 3 hr period, cultures
were washed with a solution containing physiological concentrations of Mg2+ so as to
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immediately terminate the SE-like activity [23], and the cultures were returned to
maintenance media (neuronal feed) containing carisbamate (200 µM), phenytoin (50 µM),
phenobarbital (50 µM), or control solution. After a 12 hr treatment period, the media
containing drug or control solution was removed by washing the cultures with neuronal
feed and the cultures were maintained at 37°C in a 5% CO2/95% air atmosphere. Neurons
were patch-clamped 24 hrs following this 12 hr treatment with carisbamate, phenytoin,
phenobarbital, or control solutions for the presence or absence of SREDs. Control neurons
were treated with the same number of washes and media changes as the treatment cultures.
Sham controls were also subjected to the same number of washes with respective drugs in
a solution containing normal Mg2+ concentrations. Experiments were performed on
multiple neurons from multiple culture plates, spread across several weeks. Concentrations
of all the drugs chosen to study their effect on the development and expression of SREDs
were at least twice the concentration at which they produced maximal anti-SRED effects
based on the dose-response curves generated in our laboratory (data not shown). A higher
concentration was chosen to maximize the effects of the agents studied and to determine if
this agent could produce a significant reduction in epileptiform discharges.

Cell death assay
Neuronal death was assessed at the same time point as patch clamp experiments using
fluorescein diacetate (FDA)-propidium iodide (PI) microfluorometry [24].

Three

randomly selected fields were marked and photographed. Both fluorescent and phase
bright images were captured. Neurons labeled with FDA or PI were quantified by means of
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the Ultraview image analysis software package (Perkin Elmer Life Sciences, Waltham,
MA, U.S.A.) and the fraction of neuronal death was calculated as the number of neurons
labeled by PI divided by the sum of the number of neurons labeled by PI and those labeled
by FDA. Fluorescent images were compared with phase bright images to confirm that only
pyramid-shaped neurons were counted. To quantify neuronal death with this technique,
cells in three randomly selected fields were counted manually and averaged per culture
(approximately 18–25 neurons per field).

Data analyses
Data are reported as mean ± SEM. Differences in percentage of neurons displaying
SREDs, frequency and duration of SREDs, and neuronal death were examined using oneway analysis of variance (ANOVA) followed by a post hoc Tukey test. Data were analyzed
using SigmaStat 2.0 and graphs were generated using SigmaPlot 8.02 (SPSS, Inc.,
Chicago, IL, U.S.A.). All or no effect of a given drug on SREDs was taken as the criterion
for its antiepileptic effect. In a given culture plate we patch-clamped three neurons before
moving on to another plate. All experiments were performed over a period of 3 weeks.
Depending on the number of culture plates available, we analyzed three to five culture
plates for every condition each week. Thus, the results reported are representative of
multiple culture plates belonging to different batches.

Results
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In vitro antiepileptic effects of carisbamate
Whole cell current clamp recordings obtained from neurons in cultures 2 days after a
treatment with low-Mg2+ for 3 hrs demonstrated characteristic SREDs, or in vitro seizure
events. Three SREDs lasting between 1–2 min (Figure 6-1 B) were observed in a
continuous 30 min recording. SREDs occurred spontaneously in the network of neurons,
had durations between 1 and 3 min, occurred at frequencies of up to 3-4 episodes/hr and
were observed for the life of the neurons in culture. Expansion of SREDs revealed
characteristic paroxysmal depolarization shifts, a pathophysiological characteristic
observed in epilepsy (data not shown, [23]). Age-matched control neurons never
demonstrated SREDs and had "normal" baseline activity consisting of intermittent action
potentials (Figure 6-1 A).

In contrast, bath application of carisbamate (200 µM) acutely inhibited SREDs compared
to the non-treated epileptic cultures (Figure 6-1 C). The effect of carisbamate was fully
reversible and SREDs returned upon washout of the drug from the culture medium (data
not shown). Thus, carisbamate prevented SREDs in this in vitro model of seizures. Similar
to carisbamate, bath application of clinically used AEDs, such as phenytoin (50 µM) and
phenobarbital (50 µM), also acutely inhibited SREDs (Figures 6-1 D,E). Greater than 95%
of the neurons exhibited evidence of an in vitro antiepileptic effect following application of
carisbamate/phenytoin/phenobarbital. It took approximately 10–15 min for the anti-SRED
effect to be fully manifested. In addition, there were no significant differences in
membrane potential and input resistance between age-matched control neurons, neurons
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exhibiting SREDs [23,157], and neurons treated with carisbamate acutely. Thus, neurons
displaying SREDs and carisbamate-treated neurons had mean membrane potential of −64.1
± 1.4 mV and −62.9 ± 1.1 mV and a mean input resistance of 138.5 ± 6.03 mΩ and 136.2 ±
6.7 mΩ, respectively. These values were not significantly different from each other (n = 9,
p = 0.5 and 0.8, respectively).

Effects of carisbamate on the development and expression of SREDs
As shown in Figure 6-2 A, in comparison to control neurons that did not manifest SREDs,
neurons exposed to 3 hrs of low Mg2+ treatment (n = 15 neurons, 5 culture plates)
displayed characteristic SREDs when patch clamped 36 hrs following the cessation of the
3 hrs of SE-like treatment. To investigate the effects of carisbamate on the development
and expression of SREDs, hippocampal neuronal cultures were treated with carisbamate
(200 µM) for 12 hrs after the 3 hr SE-like injury. Thus, carisbamate was not present
during low Mg2+ treatment but was present only after the SE-like injury (Materials and
Methods). Whole cell current clamp recordings from neurons (n = 18, 6 culture plates) 24
hrs following carisbamate (200 µM) treatment were devoid of any SRED activity (Figure
6-2 B). The electrographic recordings did not display any SREDs, and only manifested
occasional action potentials, resembling the recordings from sham-control neurons.
Further, neurons displaying SREDs and neurons treated with carisbamate for 12 hrs had a
mean membrane potential of −65.4 ± 1.2 mV and −64.6 ± 1.1 mV and a mean input
resistance of 133.36 ± 6.6 mΩ and 131.69 ± 8.43 mΩ, respectively. These values were not
different from each other (n = 8, p = 0.6 and 0.8, respectively). These results provide
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direct evidence that cells evaluated the day after treatment with carisbamate were still free
of in vitro seizure activity and did not develop SREDs. Thus, carisbamate had long-lasting
effects on the hippocampal neurons that were independent from its in vitro antiepileptic
effects.

Quantitation of the effects of carisbamate on the development and expression of
SREDs
Although the whole cell current clamp recordings from 18 neurons 24 hrs following
carisbamate (200 µM) treatment were devoid of any SRED activity (Figure 6-2 B), we
wanted to evaluate a larger population of neurons to carefully quantitate the effects of
carisbamate on the development and expression of SREDs. A total of 98 neurons from
different treatment groups were analyzed. For the studies in this paper, we only evaluated
recordings that were maintained for over 1 hr and some recordings were held for up to
2.5 hrs. Recordings were made from 53 neurons in carisbamate treated groups (n = 15
culture plates), 30 neurons from low Mg2+ alone groups (n = 10 culture plates), and 15
neurons from sham treated (drug control) groups (n = 5 culture plates). Greater than 97%
of the low Mg2+ alone-treated neurons displayed SREDs. In contrast, in the 53 neurons
treated with carisbamate for 12 hrs after SE-like injury, 80% of the neurons (n = 42) were
completely devoid of SREDs, and only 20% of the neurons displayed occasional
epileptiform activity (n = 11). No SREDs or hyperexcitability were observed in the control
neurons.
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We then calculated the seizure frequency by averaging total number of SREDs over 3 min
recording periods. The SRED frequency in neurons treated with low Mg2+ alone was 8.2 ±
3.6 episodes/30 min. In carisbamate treated cells, the SRED frequency was reduced to 0.58
± 0.14 episodes/30 min (Figure 6-3 B). This represented a 93% reduction in SRED
frequency in carisbamate treated neurons. We also compared the duration of SREDs
between the low Mg2+ alone and carisbamate-treated groups. The average SRED duration
in the low Mg2+-treated group was 152.4 ± 14.13 s. In the small percentage of neurons that
displayed an occasional SRED in the carisbamate treated group, the average SRED
duration was 77.6 ± 9.45 s (Figure 6-3 C). This represented an approximately 50%
reduction in the duration of SREDs in neurons from the carisbamate treated group. Thus,
carisbamate not only inhibited the development and expression of SREDs in the majority
of neurons, but it also decreased seizure frequency and duration in the few neurons that
still had an occasional epileptiform event.

Comparison of the effects of carisbamate on the development and expression of
SREDs with other AEDs
As there are currently no known agents that offer an antiepileptogenic effect in vivo, there
were no positive control drugs for comparing the ability of carisbamate to prevent the
development and expression of SREDs. However, we utilized clinically employed AEDs
that displayed anti-SREDs properties in our in vitro model as control conditions. Phenytoin
(50 µM) or phenobarbital (50 µM) was included in the neuronal feed following the 3 hr
low Mg2+ treatment (SE, Materials and Methods) for 12 hrs in an identical manner to the
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carisbamate treatment. Both phenytoin and phenobarbital at this concentration blocked
SREDs, producing the same in vitro antiepileptic effects observed following treatment
with carisbamate (Figure 6-1).

24 hrs following drug washout, neurons were patch-

clamped and observed for the presence of SREDs. As observed earlier, low Mg2+ alonetreated neurons displayed characteristic SREDs (Figures 6-1 B, 6-2 A, 6-4 A), whereas
control and carisbamate treated cells were devoid of any SRED activity (Figures 6-1 A, 6-2
B, 6-4 B). In contrast, neurons treated with either phenytoin or phenobarbital after the SElike injury (n = 10 neurons, 5 culture plates) (Figure 6-1 D,E) clearly demonstrated SREDs
similar to low Mg2+ alone-treated cells (Figure 6-4 C,D). SRED frequency in the low Mg2+
alone-treated group was 8.2 ± 3.6 episodes/30 min, while SRED frequency in the
phenytoin or phenobarbital treated groups were 8.0 ± 4.0 and 7.8 ± 4.6 episodes/30 min,
respectively. The average SRED duration in the low Mg2+ alone-treated group was 152.4
± 14.13 s, while the average SRED duration in the phenytoin- or phenobarbital-treated
groups were 162.4 ± 10.03 s and 149.4 ± 12.44 s, respectively. There were no significant
differences between low Mg2+ alone-treated and phenytoin- or phenobarbital-treated group
for these two criteria of SREDs (n = 10, p = 0.79, 0.85 and 0.43, 0.79). Thus, phenytoin
and phenobarbital did not prevent the development and expression of SREDs after SE-like
injury at concentrations that were acutely antiepileptic in vitro.

Carisbamate is neuroprotective
The neuronal injury caused by the removal of extracellular Mg2+ (in vitro SE-like injury) in
this model has been well characterized [24]. The removal of the Mg2+ block produces
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repetitive depolarizations, resulting in prolonged activation of NMDA receptors. This
persistent activation of NMDA receptors allows for excessive entry of extracellular
calcium (Ca2+), resulting in excitotoxic activation of cell-death pathways and culminating
in neuronal demise [16]. In order to investigate if carisbamate was neuroprotective, we
evaluated the effects of carisbamate exposure after the 3 hr SE-like treatment on the
viability of neurons. The fraction of neuronal death was evaluated using FDA-PI staining
24 hrs following the termination of the drug or sham control treatment employing our
previously established procedures [24]. Sham control cultures that were not exposed to
SE-like activity had a fraction of cell death of 0.117 ± 0.006. Low Mg2+ cultures exposed
to 3 hrs of SE-like injury showed fraction of cell death of 0.323 ± 0.006, which was
significantly different from sham control (n = 5; p < 0.001, one-way ANOVA, post hoc
Tukey test, Figure 6-5). In contrast, carisbamate (200 µM) treated cultures had fraction of
cell death of 0.106 ± 0.005 after 3 h of SE-like injury, which was not significantly different
from sham controls. These results provide direct evidence that carisbamate can provide
neuroprotection when administered after the SE-like activity is completed.

Discussion
This study provides direct evidence that the novel neuromodulator carisbamate not only
inhibits the development and expression of SREDs but is also neuroprotective when
administered following SE-like injury in cultured hippocampal neurons. The process of
epileptogenesis refers to the development of spontaneous recurrent seizures in a previously
normal brain [4,18,172]. Our model employs low Mg2+-induced continuous electrographic
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epileptiform discharges for 3 hrs to mimic SE-like injury in vitro. Restoration of
physiological Mg2+ concentrations terminates the high frequency epileptiform discharges
but produces a permanent plasticity change in neuronal excitability, such that the surviving
neurons manifest synchronized SREDs for their life in culture. Presence of carisbamate
following SE-like injury prevented the chronic development and expression of SREDs.
This property was unique to carisbamate, because conventional AEDs such as phenytoin
and phenobarbital failed to prevent the development and expression of SREDs following
neuronal injury. We studied phenytoin and phenobarbital because they represent two
diverse mechanisms of antiepileptic action. However, it will be important to investigate if
other AEDs prevent the development of epileptiform discharges in our model. The ability
of carisbamate to prevent the development and expression of SREDs when administered
after 3 hrs of continuous SE-like activity offers major implications in the use of this
antiepileptic agent in treating SE, because this drug is not only antiepileptic, but may also
delay the development and expression of epileptiform discharges, at least in vitro.

Our results also demonstrate that control of seizures with carisbamate may also have an
added benefit of providing a neuroprotective effect on the hippocampus. Preventing
neuronal damage after prolonged seizures is an important therapeutic goal. Several studies
have demonstrated that SE causes neuronal damage, memory loss, and several long-term
plasticity changes that can result in significant mortality and morbidity [14,74,76]. This
was an important test, because it evaluated the effects of carisbamate on neuronal death
when the drug is administered after the injury phase of SE. To our knowledge, this is the
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first demonstration of neuroprotection following SE-like activity in vitro. We also
evaluated the effects of ongoing SREDs in epileptic cultures on neuronal death by
comparing cell death using FDA-PI staining on cultures that were undergoing SREDs
versus carisbamate-treated or control sham cultures. The results of these experiments (data
not shown) demonstrated that the ongoing activity of SREDs did not increase cell death in
comparison to sham control cultures when evaluated starting 2 days after induction of
SREDs [24]. Thus, SE but not SREDs caused neuronal death in this model, and
carisbamate was able to block the cell death caused by SE-like activity. Carisbamate was
neuroprotective when given after SE-like injury and thus offers considerable therapeutic
potential in preventing brain injury following SE. However, it has been recently shown that
carisbamate reduced posttraumatic hippocampal edema without affecting neurobehavioral
or histological outcome [182]. Future studies are needed to determine the mechanism of
the neuroprotective action of carisbamate.

A long-standing question in neuroscience has been how the initial CNS injury produces
long-term plasticity changes that result in the development, expression, and maintenance of
epilepsy. Emerging research has indicated that the alterations in the levels and handling of
the ubiquitous intracellular second messenger, Ca2+, could underlie these injury-induced
long-term plasticity changes in neuronal excitability, thus leading to the proposal of the
Ca2+ hypothesis of epileptogenesis [4]. In concordance with this hypothesis, our laboratory
and many others have observed alterations in Ca2+ dynamics in all three phases of
development of acquired epilepsy [4]. Results from our laboratory have provided evidence
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that the epileptogenic and neurotoxic effects of SE are mediated both by alterations in
intraneuronal Ca2+ levels during and after SE and by altered Ca2+ homeostatic mechanisms
in the injured neurons that survive SE [32,85]. It will be insightful to investigate the
effects of carisbamate on neuronal Ca2+ dynamics and determine if this mechanism
contributes to the ability of this drug to not only prevent the development and expression
of SREDs but also afford neuroprotection following neuronal injury.
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Figure 6-1. Effects of carisbamate and other clinically used AEDs on
SREDs in cultured hippocampal neurons. A, current-clamp recording from a
representative control neuron displaying baseline activity consisting of
intermittent action potentials. B, recording from an "epileptic" neuron 3 days
following a 3 hr exposure to low Mg2+ solution demonstrates occurrence of
characteristic SREDs. Three SREDs or spontaneous seizure episodes lasting ~1–
1.5 min can be seen in this recording time frame. These SREDs occurred
throughout the life of the cultures and are indicative of the pathophysiological
"epileptic" phenotype. Effects of various AEDs on SREDs in cultured
hippocampal neurons. Application of C, carisbamate (200 µM) or D, phenytoin
(50 µM) or E, phenobarbital (50 µM) to the epileptic neurons abolished the
expression of SRED activity. The solid bar above each trace represents the
duration for drug exposure. Thus, the beginning of the bar is the point of
addition of drug.
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Figure 6-2. Effects of carisbamate on the development and expression
of SREDs. Hippocampal neuronal cultures were treated with or without
carisbamate (200 µM) immediately following the low Mg2+ treatment.
Drug was washed off the next day and 24 hrs later neurons were patch
clamped. A, representative control neuron displaying characteristic SREDs
24 hrs following the sham washout. The recording is representative of 30
different neurons. B, current clamp recordings from a representative
neuron 24 hrs following carisbamate (200 µM) washout. The neuron was
devoid of any SRED activity and manifested occasional action potentials
resembling the recordings from sham-control neurons. The recording is
representative of 53 different neurons.
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Figure 6-3. Analyses of the effects of carisbamate on the development
and expression of SREDs. A, SRED frequency in low Mg2+ alone-treated
group was 8.2 ± 3.6 episodes/30 min. Phenytoin- and phenobarbital-treated
groups had SRED frequencies of 8 ± 2 and 7.8 ± 2.2 episodes/30 min,
respectively, while the carisbamate treated group displayed a SRED
frequency of 0.58 ± 0.14 episodes/30 min. B, average SRED duration in
the low Mg2+ alone treated group was 152.4 ± 14.13 s. Phenytoin and
phenobarbital groups had average SRED durations of 162.4 ± 10.03 s and
149.4 ± 12.44 s, respectively, while the average SRED duration of the
carisbamate-treated group was 77.6 ± 9.45 s (*p < 0.001, one-way
ANOVA, post hoc Tukey test).
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Figure 6-4. Comparison of the effects of carisbamate on the
development and expression of SREDs with other AEDs. A,
recordings from a low Mg2+-treated neuron displaying characteristic
SREDs. B, treatment with carisbamate (200 µM) following SE-like
injury prevents the development and recurrence of SREDs. No SREDs
are observed in this neuron even after removal of carisbamate. C and D,
other clinically used AEDs such as phenytoin (50 µM) and phenobarbital
(50 µM) did not prevent the development and expression of SREDs. All
the patch clamp recordings were performed 24 h following the drug
washout.
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Figure 6-5. Neuroprotective effects of carisbamate. Fraction of cell
death was analyzed using FDA-PI staining after the removal of the
drug. Sham control cultures were not exposed to SE, but were handled
similar to other cultures. They displayed a fraction of cell death of
0.117 ± 0.006. Cultures exposed to 3 hrs of low Mg2+ SE showed a
fraction of cell death of 0.323 ± 0.006 (n = 5; *p < 0.001, one-way
ANOVA, post hoc Tukey test). Carisbamate (200 µM) treated cultures
had a fraction of cell death of 0.106 ± 0.005 when administered after 3
hrs of SE-like injury. This fraction of cell death was not significantly
different from sham controls
.
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Chapter 7: The Novel Anti-Epileptic Drug Carisbamate (RWJ333369)
Modulates Calcium and Restores Calcium Homeostatic Mechanisms in
Hippocampal Neuronal Cultures

Introduction
Approximately 2% of the world’s population is affected by epilepsy, a common
neurological condition characterized by spontaneous, recurrent seizures [81]. 40% of all
cases of epilepsy develop following some neuronal injury, such as status epilepticus (SE),
stroke, or traumatic brain injury (TBI) and are, thus, classified as acquired epilepsy (AE)
[81,183]. This transformation can be characterized as a progression through three stages:
injury, epileptogenesis, and the maintenance of chronic epilepsy.

During the

epileptogenesis phase, recurrent seizures may not be present; however, neurons are
undergoing plasticity changes that will ultimately lead to the expression of epilepsy.
Understanding the pathophysiological changes that occur during this process is important
in the development of anti-epileptogenic agents to prevent the ultimate development of
epilepsy. While much progress has been made in the development of new anti-epileptic
drugs (AEDs), or anti-convulsants, currently there are no therapeutics that can prevent
epileptogenesis following neuronal injury. Such compounds that can be administered after
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brain injury and halt epileptogenesis are clinically very important, and the development of
these agents represents an important area of research.

Carisbamate (RWJ333369) is a novel neuromodulator that is currently in phase II clinical
trials for the treatment of epilepsy [178,179]. It has been shown that this drug, a carbamate
closely related to felbamate, not only demonstrates anti-convulsant properties but also
displays a wide margin of safety in humans [178,179,181]. More recently, we have
demonstrated that carisbamate is able to inhibit spontaneous recurrent epileptiform
discharges (SREDs), the in vitro correlate to epilepsy, in hippocampal neuronal cultures
[184]. In the same low Mg2+ model, we were also able to demonstrate that when given
following low Mg2+-induced in vitro SE, carisbamate prevented the development of
SREDs even following the removal of the drug from the system [185]. This is the first
time a drug has been shown to be anti-epileptogenic in this in vitro model; thus,
elucidating the mechanism of action is critical to understanding how anti-epileptogenic
agents work. Currently the mechanism of action behind this drug is not known so many
groups are actively investigating potential mechanisms responsible for both its anticonvulsive and its anti-epileptogenic properties.

This study was initiated to elucidate a potential mechanism of action behind the ability of
carisbamate to inhibit epileptogenesis in the low Mg2+, in vitro hippocampal neuronal
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culture model of SE-induced AE. This model is well-characterized and used widely.
Moreover, due to several similarities between the model and both in vivo models and the
human condition, it provides a useful tool in preliminary studies investigating
pathophysiological mechanisms and potential therapeutics. The changes in Ca2+ dynamics
observed in the rat pilocarpine model of SE-induced AE are also observed in the in vitro
model. Essentially, it has been demonstrated that during in vitro SE, [Ca2+]i increases
significantly. These elevations are maintained well past the duration of the injury, and
while they decrease over time, they remain significantly elevated for at least 48 hrs post-in
vitro SE.

Similar changes in Ca2+ also exist in the rat pilocarpine model, wherein

hippocampal neuronal [Ca2+]i remains elevated only in those animals that later develop
epilepsy [32]. As an important second messenger, such long-lasting increases in [Ca2+]i
have the potential to affect neurotransmission, gene transcription, and neuronal plasticity
leading to the development of chronic epilepsy. Moreover, studies that have blocked the
elevations in [Ca2+]i by administering NMDA antagonists before SE have prevented the
development of epilepsy; therefore, this suggests that these alterations in Ca2+ are
responsible for epileptogenesis and the maintenance of the epileptic phenotype. Thus,
examining how carisbamate affects these changes in Ca2+ is important in understanding
epileptogenesis and potentially, how this drug affects neuronal plasticity.

Materials and Methods
Reagents
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Carisbamate was provided by Johnson & Johnson (Pharmaceutical Research &
Development L.L.C., Titusville, NJ, U.S.A.). Carisbamate was dissolved in sterile water
made slightly basic with sodium hydroxide and diluted to final concentration in
physiologic basal recording solution (pBRS).

Hippocampal neuronal culture preparation
Preparation of primary mixed hippocampal neuronal culture was performed as previously
described [23].

In summary, hippocampal cells were isolated from 2-day post-natal

Sprague-Dawley rats (Harlan, Frederick, MD). Hippocampal neurons (8.75x104) were
plated onto a glial support layer that was previously plated onto poly-L-lysine (0.05
mg/ml) coated Lab-Tex glass chambers (Nalge-Nunc International, Naperville, IL).
Cultures were maintained at 37°C in a 5% CO2/95% O2 incubator and fed twice weekly
with neuronal feed containing 20% conditioned media, as described previously [23,50].
All experiments were performed on neurons maintained for 14-17 days in vitro to ensure
proper development. All procedures adhered strictly to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by Virginia
Commonwealth University’s Institutional Animal Care and Use Committee.

Ca2+ microfluorometry
Primary hippocampal cultures were loaded with Fura-2 acetoxymethyl ester (Fura-2AM)
and then placed on the 37°C stage of an Olympus IX-70 inverted microscope (Olympus,
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Center Valley, PA) coupled to an ultra-high-speed fluorescence imaging system. Ratio
images were acquired using alternating excitation wavelengths (340/380 nm) with a filter
wheel (Sutter Instruments, Novato, CA) and fura filter cube at 510/540 nm emissions with
a dichroic mirror at 400 nm [94]. MetaFluor (Olympus, Center Valley, PA) was used for
image acquisition and analysis. Images were acquired from any given field at various time
intervals depending on the specific experiment and background fluorescence was
subtracted from all acquired data by imaging hippocampal neuronal cultures that were not
loaded with Fura-2AM [94].

Glutamate challenge: assessing Ca2+ homeostatic mechanisms
In order to assess Ca2+ homeostatic mechanisms, neurons were loaded with Fura-2AM
according to previously described protocols [50] and challenged with 50 µM glutamate for
2 minutes. After 2 min, the cultures were washed with pBRS to remove the glutamate.
340/380 ratio images were captured every 30 seconds to record both the response to and
recovery from glutamate exposure, as described previously [4].

Data analysis
Data were statistically analyzed using StatView (Version 5.0.1).

Experiments were

repeated over a period of a few weeks so as to sample from different culture batches. The
significance of the data was tested by one-way analysis of variance (ANOVA), or one-way
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repeated measures (RM) ANOVA followed by Fisher’s post-hoc test when appropriate. P
< 0.05 was considered significant for all data analysis.

Results
It has been demonstrated that in vitro SE causes long-lasting elevations in intracellular
Ca2+ ([Ca2+]i). The ability to lower [Ca2+]i post-SE to normal, baseline concentrations may
help prevent the second messenger effects that lead to plasticity changes and the
development of epilepsy.

Carisbamate restores Fura-2 Ca2+ ratios following low Mg2+-induced in vitro SE
During treatment with low Mg2+(in vitro SE), cells exhibited increased [Ca2+]i as indicated
by an elevation in 340/380 ratios to approximately 0.78 (Figure 7-1). Following the low
Mg2+ treatment, neurons were returned to Mg2+-containing solution containing either
carisbamate (200 µM) or vehicle at time point 0 on the x-axis. In cells treated with the
drug following low Mg2+, the 340/380 ratios are lowered rapidly to ratios observed in
naïve neurons, unlike the vehicle-treated neurons, which continue to exhibit 340/380 ratios
that are significantly elevated. Thus, it appears that when given acutely following in vitro
SE, carisbamate is able to significantly lower [Ca2+]i.

Basal Ca2+ levels are maintained 24 hours post-carisbamate washout
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Carisbamate, when used following in vitro SE, was able to maintain baseline [Ca2+]i for at
least 24 hrs after drug washout. After neurons were returned to normal, Mg2+-containing
solution following treatment with low Mg2+, the cells displayed SREDs. SREDs are the in
vitro correlate to epilepsy and these ‘epileptic’ cells exhibit paroxysmal depolarization
shifts. Similarly to the experimental protocols used in the study that demonstrated that
carisbamate was anti-epileptogenic (prevented the development of SREDs when
administered immediately post-SE) [185], following 3 hrs of low Mg2+ treatment cells
were returned to maintenance media containing vehicle or 200µM carisbamate. 12 hrs later
the drug was washed out of the hippocampal neuronal cultures, and 24 hrs following the
removal of the drug the neurons were imaged to determine [Ca2+]i. At this time point,
drug-treated neurons fail to display SREDs, in contrast to the vehicle-treated, or ‘epileptic’
neurons [185]. Moreover, as shown in Figure 7-2, the carisbamate-treated neurons showed
Fura-2 ratios significantly lower than the vehicle-treated neurons that displayed SREDs,
0.328 ± 0.025 and 0.424 ± 0.019 respectively (n=5; P<0.001, one-way ANOVA, post-hoc
Fisher test). Moreover, the Fura-2 ratio observed in the drug-treated cells is consistent with
that of the sham controls, 0.314 ± 0.018. This demonstrates that caribamate, as far out as
24 hrs post-drug washout, was able to maintain [Ca2+]i at baseline values.

Carisbamate-treated neurons exhibit enhanced recovery following glutamate
challenge
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It has been demonstrated that following treatment with low Mg2+, ‘epileptic’ neurons that
display SREDs also show altered homeostatic mechanisms [4]. Therefore, if these neurons
are briefly stimulated with glutamate, they are unable to restore normal [Ca2+]i in the cell
[4]. In contrast, naïve or sham-control neurons have intact homeostatic mechanisms and
are thus, able to recover from such challenges [4].

Following 3 hrs of treatment with low Mg2+ (in vitro SE), cells were returned to
maintenance media containing vehicle or carisbamate (200µM). 12h later the drug was
washed out of the cultures and 24h post-washout the carisbamate-treated neurons were
loaded with the Ca2+ indicator Fura-2AM. These neurons were then subjected to glutamate
stimulation (50µM, 2 min). The neurons that were treated with carisbamate showed an
increased ability to recover from this challenge when compared to vehicle-treated
(epileptic) neurons (Figure 7-3). Glutamate elicited an increase in [Ca2+]i in both treatment
groups. Neurons treated previously with carisbamate were able to restore [Ca2+]i to basal
levels in 25 min (consistent with that observed in sham controls, data not shown but as
observed previously [4]). Vehicle-treated, ‘epileptic’ neurons showed a diminished ability
to recover from this challenge and in 25 min, [Ca2+]i is still elevated at 150% of baseline.
Thus, SE induces long-lasting alterations in Ca2+ homeostatic mechanisms that treatment
with carisbamate is able to restore.
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Discussion
The results of this study demonstrate that the novel AED, carisbamate, when administered
immediately following in vitro SE, is able to lower [Ca2+]i to baseline concentrations
observed in control neurons in the hippocampal neuronal culture model of SE-induced AE.
Moreover, in order to test whether immediate treatment post-SE was able to cause more
long-lasting changes in these neurons, the drug was washed out of the system 12 hrs posttreatment. Interestingly, 24 hrs after the wash-out of drug, the carisbamate-treated neurons
appear to have normal [Ca2+]i and unaltered homeostatic mechanisms, unlike the low Mg2+
neurons that were not treated with the drug. At this same time point (24 hrs following
wash-out of drug), the neurons that were treated with carisbamate also fail to display
SREDs.

Thus, it appears that lowering [Ca2+]i and the restoration of homeostatic

mechanisms correlates with a positive outcome, the prevention of SRED development. In
the model of SE-induced AE that was used in these studies, hippocampal neuronal cultures
were treated for 3 hrs with low Mg2+ to trigger high frequency, SE-like activity. The
ability to treat these neurons after an insult such as SE and prevent the process of
epileptogenesis- wherein cells begin to express SREDs- is important in addressing the
significant clinical challenge of developing anti-epileptogenic agents.

Carisbamate was initially developed to be an effective AED that did not produce the
unwanted side effects observed in earlier generations of carbamates such as felbamate.
Several studies have started utilizing this drug in various models of epilepsy, and have
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found that it displays potent neuroprotective, as well as anti-convulsant properties [178181]. However, despite these positive results, the mechanisms of action behind these
properties are currently unknown. Many groups have initiated studies aimed at better
understanding how this drug works. Some groups have proposed that the anti-convulsant
effects are mediated by voltage-gated sodium channels [186] and another study has
affirmed these results by showing that caribsmate is able to inhibit sustained repetitive
firing (SRF), an effect thought to be dependent on voltage-gated sodium channels [184].
However, the effect that carisbamate has on other channels has not been as thoroughly
examined.

Moreover, no studies besides the current one have examined potential

mechanisms of action behind its anti-epileptogenic properties in the in vitro model. The
ability to modulate Ca2+, while perhaps not important in contributing to the anti-convulsant
properties of carisbamate, may prove to be an important feature in terms of preventing
epileptogenesis.

Ca2+ plays an important role as an ubiquitous second messenger; thus, alterations in [Ca2+]i
have been shown to significantly affect cellular functions. While it has been repeatedly
demonstrated that injuries such as SE can cause profound injury to neuronal cells and
trigger the activation of cell death pathways [187,188], no studies have been successful in
preventing epileptogenesis following neuronal injury. Studies in our lab have implicated
Ca2+, and Ca2+ regulatory systems, as playing a key role in the development of epilepsy
after an initial insult [32,63,85]. During neuronal injury, glutamate is released which
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stimulates a variety of receptors, one of which is the Ca2+-permeable NMDA receptor [4].
This event causes an acute elevation in [Ca2+]i, which is then maintained or perpetuated by
Ca2+-induced Ca2+ release systems and inhibition of Ca2+ uptake by sarco-endoplasmic
reticulum Ca2+-ATPase (SERCA). Increased [Ca2+]i leads to an elevation in nuclear Ca2+
levels, and consequently signals the transcription of several epileptogenic/pro-apoptotic
genes.

These events cause alterations in neuronal functions such as excitability,

transmitter release, receptor expression, and synaptic plasticity [79]. Thus, a drug that can
affect [Ca2+]i and Ca2+ homeostatic mechanisms, and in doing so prevent the plasticity
changes that lead to epilepsy, may prove to be an important step in the search for antiepileptogenic agents.
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Figure 7-1. Carisbamate restores Fura-2 Ca2+ ratios following low
Mg2+-induced in vitro SE. Following 3 hrs of in vitro SE (time=0),
cells were treated with either carisbamate (200µM, clear white circles)
or vehicle (solid black circles). 340/380 ratios were recorded every 30
sec for 60 mins. Carisbamate is able to significantly lower [Ca2+]i to
levels in naïve, control neurons, whereas the vehicle-treated neurons,
maintain persistent elevations. *p<0.01.
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Figure 7-2. Basal Ca2+ levels are maintained 24 hours postcarisbamate washout.
Carisbamate (200µM), when used
following in vitro SE, was able to maintain baseline [Ca2+]i for at
least 24 hrs after drug washout. At this time point, Fura-2 ratios in
the drug-treated group were significantly lower than the vehicletreated (epileptic) neurons, 0.328 ± 0.025 and 0.424 ± 0.019,
respectively. The Fura-2 ratio observed in the drug-treated cells
was consistent with that of the sham controls, 0.314 ± 0.018.
*p<0.001, n=5 plates per group.
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Figure 7-3.
Carisbamate-treated neurons exhibit enhanced
recovery following glutamate challenge. Treatment with carisbamate
(200µM) following in vitro SE restores Ca2+ homeostatic mechanisms
for at least 24 hrs post-washout of the drug. Carisbamate-treated
neurons (clear white dots) show enhanced recovery from glutamate
stimulation (50µM, 2min) when compared to vehicle-treated,
‘epileptic’ neurons (solid black dots).
Neurons treated with
carisbamate are able to restore [Ca2+]i to basal levels in 25min.
Vehicle-treated (epileptic) neurons show a diminished ability to recover
from this challenge and in 25min [Ca2+]i is elevated, 150% of baseline.
*p<0.05, n=5 plates per group.
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Chapter 8: Discussion

The results from these studies suggest that the Ca2+ plateau that exists in the in vivo
pilocarpine model of SE-induced AE is also observed in the in vitro, low Mg2+ model. It
appears that SE causes a tremendous increase in [Ca2+]i which decreases slowly over time,
but overall is maintained for at least 48 hrs post-SE. These sustained elevations in [Ca2+]i
may be responsible for long-term plasticity changes, ultimately leading to the development
of SREDs, or in vitro epilepsy. Understanding the physiology behind this elevation in Ca2+
may offer new therapeutic targets to provide neuroprotection and, potentially, prevent
epileptogenesis following neuronal injuries such as SE.

It has been demonstrated that NMDA receptors are largely responsible for the Ca2+ influx
into the cell during excitatory events such as SE. Studies have demonstrated that pretreatment with an NMDA antagonist prior to SE inhibited the long-lasting elevations in
[Ca2+]i observed post-SE, improved the outcome of SE, and prevented the development of
epilepsy [41,43]. However, from a clinical standpoint, treating a patient prior to neuronal
injury in the hopes of preventing epileptogenesis is not a feasible approach. Thus, the
downstream consequences of NMDA receptor-mediated increases in [Ca2+]i remain an
important area of research in the development of potential agents to halt the development
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of AE. The period between the neuronal injury and the actual development of chronic
epilepsy represents a potential therapeutic window of opportunity wherein the plasticity
changes that lead to epilepsy may be inhibited.

Thus, our approach was to examine the period between SE and chronic epilepsy to
determine which systems contribute to the alterations in [Ca2+]i and to test whether
manipulating these systems pharmacologically could halt epileptogenesis. The in vitro
hippocampal neuronal culture model provides an excellent tool for this endeavor in that,
unlike in vivo systems, high-throughput screenings of various drugs could be performed
under the strict environmental control to prevent confounders. Moreover, multiple assays
could be performed to determine how each drug affected Ca2+ regulatory systems, cell
viability, [Ca2+]i, and the development of SREDs. Therefore, the observation that the in
vitro model mimics the in vivo model in terms of Ca2+ changes is an important finding that
will aid in the testing of new therapeutic approaches before commencing such studies in a
more complex in vivo model.

Several studies have examined various regulators of intracellular Ca2+ at myriad time
points before, during, and after SE. These regulators include CICR systems (IP3 and
RyR), Ca2+ binding proteins, Ca2+-regulated enzymes, and Ca2+ channels on the cell
membrane. In these studies, we focused on the RyR, a tetrameric Ca2+ channel present on
the endoplasmic reticulum. This channel is able to gauge [Ca2+]i and then release Ca2+
from intracellular stores based on the cytoplasmic concentration. Studies on the RyR have
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utilized dantrolene, a pharmacological inhibitor of the receptor, as a tool to investigate the
role of the channel in several pathologies. In the field of epilepsy, several groups have
used dantrolene prior to the inciting injury to demonstrate that treatment with this drug
decreases neuronal cell death [97]. Two studies have demonstrated in both animal and
slice models that dantrolene protects neurons from kainic acid-induced apoptosis, thus
suggesting that RyRs may play a role in mediating cell death triggered by kainic acid
[189,190]. In addition, Pelletier et al. demonstrated that RyRs are involved in cell death
produced in a tetanic stimulation in vitro model of seizures [191]. Other labs have shown
that dantrolene can prevent the acquisition of amygdaloid kindling, another model of
acquired epilepsy [105]. While these studies have made novel findings regarding the role
of RyR in seizure-induced cell death, no study has examined whether dantrolene could be
neuroprotective when given post-neuronal injury and if so, whether this neuroprotection
could also contribute to anti-epileptogenic properties.

One group has performed several interesting studies in a model of ventricular arrhythmias
in the heart and has demonstrated that increased phosphorylation of the RyR can cause
them to be “leaky” and release more calcium into the cytoplasmic space [99,100]. This
leak leads to the arrhythmia and can be controlled by treatment with a benzothiazepine,
which stops the leak by increasing the affinity of a protein, calstabin with the receptor
[100]. We demonstrated in the in vivo pilocarpine model that the expression of RyR does
not change during SE, or at 1 hr, 1 day, 1 wk, or 7 wks post-SE. Thus, we hypothesized
that SE triggered an increase in phosphorylation of the receptor, thereby leading to
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increased Ca2+. This hypothesis was confirmed with western blot using an antibody for the
phosphorylated form of the receptor. We demonstrated that in the pilocarpine model of
SE-induced AE, during the period of epileptogenesis hippocampal neurons show a marked
increase in the phosphorylated form of the receptor. This may potentially explain how
dantrolene, a RyR inhibitor, was effective in lowering Ca2+ to baseline levels and
preventing epileptogenesis. The similarities between the ventricular arrhythmia model and
epilepsy are striking: both are disorders of cellular hyperactivity triggered by ionic
imbalances, RyR are important components of both cardiac cells and neurons, and
benzothiazepines effectively treat the arrhythmias and benzodiazepines are the most
prevalent treatment for epilepsy.

Thus, these studies in cardiac tissue support our

hypothesis and also suggest that Ca2+ dysregulation could be a result of alterations to the
RyR. This represents an interesting and novel area of future research, with clinically
relevant implications in both the fields of neurology and cardiology.

These studies demonstrating the role of RyR in ventricular arrhythmias and in seizureinduced cell death served to bolster our own studies. The in vitro, low Mg2+ model was
utilized to determine if treatment with dantrolene following SE could lower [Ca2+]i and
prevent the development of SREDs. In this model, we observed that dantrolene is able to
lower [Ca2+]i to concentrations observed in control neurons, maintain these baseline levels,
offer neuroprotection, and inhibit the development of SREDs.

These results, in

combination with the results from other studies, make dantrolene a potential therapeutic
candidate to be tested in an in vivo model.
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Our studies have also shown that the novel AED, carisbamate, appears to block SREDs
when used on “epileptic” neurons and prevents the development of SREDs when
employed immediately post-SE. We found that the drug had to be present in the cultures
to inhibit SREDs; the episodes returned following wash-out of the drug. Interestingly,
however, when cultures were treated with the drug for 12 hrs after low Mg2+ and examined
24 hrs after wash-out of the drug, the neurons failed to display SREDs.

We also

demonstrated that this drug not only lowered [Ca2+]i post-SE but was also able to restore
Ca2+ homeostatic mechanisms. This is the first account of this drug exhibiting antiepileptogenic properties and further studies are being conducted to determine if similar
properties exist when used in vivo. We are interested in more thoroughly examining how
this drug affects regulators of intracellular Ca2+ release such as the RyR and IP3R.

We have also utilized another commonly used AED, levetiracetam. No mechanism of
action is known for this drug, even though it is used frequently in clinical settings [110]. It
is known that levetiracetam does not directly affect GABAergic neurotransmission or
interact with the benzodiazepine binding site [111-113,192].

Thus, the effect of

levetiracetam on Ca2+ and Ca2+ regulatory systems proved to be an interesting, unexplored
potential mechanism of action. We demonstrated in hippocampal neuronal cultures that
this drug did not affect baseline [Ca2+]i in naïve neurons; however, when RyR and IP3R
were over-stimulated, the drug inhibited CICR mediated through both of these systems.
The ability to modulate Ca2+ levels inside hippocampal neurons is an important
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characteristic, and may make the drug an ideal candidate in neuroprotection following
neuronal injury.

All of these studies have aimed at modulating [Ca2+]i, and in doing so, determining the role
that various calcium regulatory systems have in epileptogenesis and, to some extent,
neuronal plasticity. The question of how Ca2+ affects plasticity is of utmost importance in
understanding basic neuronal functions such as learning and memory, as well as long-term
neuronal adaptations. Moreover, the observation that elevations in [Ca2+]i are maintained
post-SE in animals that develop epilepsy is not limited to models of SE-induced AE.
Other conditions such as stroke and TBI can also lead to the development of chronic
epilepsy and alterations in [Ca2+]i have been observed in these models. Finding common
pathophysiologic mechanisms that lead to the development of a single phenotype—
epilepsy—following distinct injuries is important in understanding neuronal plasticity and
in creating new treatments to prevent epileptogenesis.

Each of these injuries, while

resulting from different etiologies, is excitotoxic and has been shown to trigger the massive
release of glutamate, activation of NMDA receptors, and finally, influx of Ca2+ into the
cell [4]. As a ubiquitous second messenger, this increase is enough to trigger significant
downstream effects that can affect neurotransmission, transcription, cell death pathways,
and ultimately, the fate of the neuron. Therefore, the examination of Ca2+ dynamics in
various models of injury-induced epilepsy may be of great clinical importance and may aid
in our understanding of the precise role between Ca2+ and epileptogenesis.
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Currently, approximately 30% of epileptic patients are resistant to conventionally used
AEDs [72,84]; therefore, new treatment modalities are needed. In the development of new
AEDs, many research groups screened large numbers of drugs in in vivo models in the
hopes that they would find potential therapeutic agents. Once drugs were found that
displayed these properties, the cellular and molecular mechanisms behind the anticonvulsant action were studied. We are only now starting to understand the specific effect
that these agents have on individual channels, receptor expression, and myriad cellular
processes. While these studies contributed greatly to the current body of knowledge on
epilepsy, such massive screening efforts are not necessarily the most appropriate or
efficient in the search for anti-epileptogenic agents.

Research groups studying anti-

epileptogenic drugs are focusing on pathophysiological mechanisms as a means of better
understanding the process of epileptogenesis and as targets for therapeutics [193]. This
approach has led to a significantly more thorough understanding of mechanisms of
excitability and plasticity and the clinical implications of utilizing these studies to affect
patient care are tremendous.

Thus, observations such as changes in Ca2+ and Ca2+

homeostatic mechanisms represent a clinically interesting area of future study with
therapeutic implications.

It should be noted that while many Ca2+ channel antagonists have been shown to exhibit
anticonvulsive properties or potentiate the effects of AEDs both in experimental models
and in clinical trials [90,91], there are also several reports that other Ca2+ channel inhibitors
are completely ineffective [91].

Even less work has been done examining the effect of
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Ca2+-modifying agents in models of epileptogenesis, and the data demonstrating the anticonvulsive properties of these drugs suggests that numerous types of inhibitors will have to
be tested. One study has shown that the NMDA antagonist, MK-801, was effective in
decreasing the number of animals that developed chronic epilepsy following electricallyinduced SE [43]. However, in the kainic acid-induced SE model, MK-801 did not prevent
the development of epilepsy [92].

Conflicting results between different models of

epileptogenesis have made the search for new therapeutics challenging [93] and have
underscored the importance of utilizing several different models of epileptogenesis.

Studies aimed at discerning whether lowering Ca2+ to basal levels can diminish or halt the
process of epileptogenesis may be of importance. The long-lasting Ca2+ plateau observed
post-injury appears to be controlled by a multitude of channels, Ca2+ binding proteins, and
other regulators.

Currently, Ca2+ modifying agents have been employed for other

pathologies of the CNS.

For example, the NMDA antagonist, memantine, has been

utilized in patients with Alzheimer’s disease [89]. Interestingly, one Phase II clinical trial
administered the Ca2+-chelating agent, DP-BAPTA, to patients following stroke and found
that this drug improved the National Institutes of Health stroke scores with no major
cardiovascular or neurological side effects even at the highest dose tested [88]. The ability
to modulate Ca2+ without causing long-lasting, severe side effects is important. Since Ca2+
is found ubiquitously in the body and is necessary for many cellular processes, the
potential side effects of altering Ca2+ pharmacologically could be tremendous and thus,
represent a major hurdle in the utilization of Ca2+ modifying drugs.
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The ability to

synthesize these observations on altered Ca2+ dynamics with those from molecular-genetic
studies identifying potential genes involved in epilepsy could provide novel insight in the
generation of new anti-epileptogenic targets.
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